CORONA Main Coronavirus thread

Heliobas Disciple

TB Fanatic
(fair use applies)


Biden won't veto Republican-led bill ending COVID emergency
SEUNG MIN KIM and LISA MASCARO
Wed, March 29, 2023, 9:23 PM EDT

WASHINGTON (AP) — President Joe Biden won’t veto a Republican-led measure to end the national COVID emergency, despite having expressed strong objections against it earlier this year, ensuring the bill is on an easy path to becoming law.

It marks the second time in the new Congress that the Biden administration has signaled opposition to a Republican measure, rallying most Democrats in Congress to vote against it, only to soften its stance and let the legislation eventually become law.

Just weeks ago, Biden stunned many fellow Democrats when he declined to veto a Republican-led bill to upend a new criminal code for the District of Columbia he and others in the president's party opposed, allowing the GOP's tough-on-crime push into the local government to become law.

Republicans celebrated the turn of events Wednesday as a sign of their newfound influence in divided Washington, while Democrats quietly complained that the Biden administration had shifted its views.

But the White House stood firm, and the Senate gave final approval, 68-23, sending the bill to Biden's desk.

A White House official said that when the House Republicans were first preparing to vote on the bill at the start of the year, it would have lifted the national emergency declaration for the coronavirus pandemic in February.

But now, it's much closer to the White House's own plan to wind down COVID national emergency status on May 11.

The president still strongly opposes the legislation, said the official, who was granted anonymity to discuss the situation. But if this bill comes to Biden's desk, he will sign it, the official said.

Ahead of voting, Sen. Roger Marshall, R-Kan., one of the bill’s main sponsors, said he hoped “that the rumors are true — that the president will finally sign this legislation.”

The legislation is a simple one-line measure saying that national emergency declared on March 13, 2020, “is hereby terminated.”

It comes from one of the more conservative Republicans in the House, Rep. Paul Gosar of Arizona, and draws on Republican-led opposition to mask mandates, lockdowns and others precautions that were put in place to stem the spread of the virus during the pandemic. It was among the early bills the new House GOP put forward at the start of the year.

At the time, the administration warned the proposal would cause chaos. More than 197 Democrats in the House voted against it.

“An abrupt end to the emergency declarations would create wide-ranging chaos and uncertainty throughout the health care system — for states, for hospitals and doctors’ offices, and, most importantly, for tens of millions of Americans,” the administration said in a formal statement of administrative policy.

In the days leading up to the House vote, the Biden administration announced its own plan to wind down emergency status on May 11, three years after the virus outbreak.

The administration's announcement meant the federal coronavirus response would be treated more as an endemic threat to public health that could be managed through agencies’ normal authorities, rather than pandemic status.

Just a few weeks ago Biden signed another Republican-led bill into law that would nullify the District of Columbia's revamp of its criminal code. The administration had previously said it opposed that bill.

On Wednesday, Republicans on the House Oversight Committee voted to overturn a police reform package passed by the D.C. Council.
 

Heliobas Disciple

TB Fanatic

Ironically, yesterday I mentioned the past posts about Ig4 immune tolerance studies and today it's back in the news. See the links in the quoted text if you want to see what was posted back then.


(fair use applies)


COVID-19 News: IgG4 Antibodies Produced by mRNA Shots Generate Immune Tolerance To SARS-CoV-2’s Spike Protein By Immune System Suppression
Thailand Medical News
March 29, 2023

A new international study has found that IgG4 antibodies produced by mRNA shots generate immune tolerance to SARS-CoV-2’s spike protein by immune system suppression.

As a result of the health crisis caused by SARS-CoV-2, the creation of a new vaccine platform based on mRNA was implemented. Globally, around 13.32 billion COVID-19 vaccine doses of diverse platforms have been given, and up to this date, 69.7% of the total population received at least one injection of a COVID-19 vaccine.

Though these vaccines prevent hospitalization and severe forms of the disease, increasing evidence has shown they do not produce sterilizing immunity, allowing individuals to suffer frequent re-infections.

Alarmingly however, recent research has also raised concerns that mRNA vaccines could induce immune tolerance, which, added to that caused by the virus itself, could complicate the clinical course of a COVID-19 infection.

In addition, recent investigations have found high IgG4 levels in individuals who were administered two or more injections of mRNA vaccines. It has been suggested that an increase in IgG4 levels could have a protecting role by preventing immune over-activation, similar to that occurring during successful allergen-specific immunotherapy by inhibiting IgE-induced effects.

Cumulatively, evidence suggests that the reported increase in the IgG4 levels detected after repeated vaccination with the mRNA vaccines is not a protective mechanism; rather, it may be a part of the immune tolerance mechanism to the spike protein that could promote unopposed SARS-CoV2 infection and replication by suppressing natural antiviral responses.

IgG4- induced suppression of the immune system due to repeated vaccination can also cause autoimmune diseases, promotes cancer growth, and autoimmune myocarditis in susceptible individuals

The study team comprised of scientists from the following entities:

-University of South Florida-USA

-King Abdulaziz University-Saudi Arabia

-City for Scientific Research and Technology Applications-Egypt

-Cross Cancer Institute, Alberta Health Services-Canada

-University of Guadalajara-Mexico

The increase in IgG4 levels observed after mRNA vaccine administration may be attributed to the unique characteristics of the mRNA vaccine platform, such as the high mRNA concentration and the induction of strong and sustained immune responses. This is supported by the fact that anti-S1 IgG4 responses were not observed in individuals who received the adenovirus-based vaccine.

The optimal dose of vaccine antigen is a crucial factor in the development of a robust and effective immune response. While high antigen doses can cause immune exhaustion and tolerance, low antigen doses may result in a suboptimal immune response. Studies have shown that lower vaccine antigen doses can result in more positive T cell responses and better preventive efficiency. Thus, finding the ideal antigen dose for immunoth erapy is crucial to establish a strong and effective immune response.

The study team concluded that the mRNA shots, particularly the mRNA-1273 vaccine, have been found to induce prolonged IgG4 responses in uninfected individuals, which is not observed with other vaccine platforms. The increase in IgG4 levels may be attributed to the unique characteristics of the mRNA vaccine platform, such as high mRNA concentration and sustained immune responses. The optimal vaccine antigen dose is a crucial factor in developing a robust and effective immune response. Lower vaccine antigen doses may result in more positive T cell responses and better preventive efficiency.

The study findings were published on a preprint server and are currently being peer reviewed. IgG4 Antibodies Induced by mRNA Vaccines Generate Immune Tolerance to SARS-CoV-2’spike Protein by Suppressing the Immune System

Numerous recent studies and COVID-19 News coverages have raised concerns about mRNA-based COVID-19 vaccines potentially inducing tolerance against the spike protein. After multiple Pfizer vaccine doses, research has shown an increase in non-neutralizing IgG4 antibodies, which can be both protective and pathogenic. While this increase in IgG4 levels might prevent immune over-reactivity in some cases, it may also lead to unintended negative consequences, such as inhibiting the immune system's ability to detect and attack the virus.

The immune tolerance mechanism induced by mRNA vaccines could have at least six negative unintended consequences:

-Increased vulnerability to re-infection with new Omicron subvariants, potentially causing severe harm or death in individuals with comorbidities or compromised immune systems.

-Temporarily impaired interferon signaling and immune suppression, leaving the individual vulnerable to other pathogens, re-activating latent infections, or allowing uncontrolled growth of cancer cells.

-Enabling SARS-CoV-2 persistence in the host, potentially leading to chronic infections similar to those caused by hepatitis B, HIV, and hepatitis C viruses.

-A combination of immune suppression from both SARS-CoV-2 infection and vaccination may explain autoimmune conditions, cancers, re-infections, and deaths associated with COVID-19 vaccinations.

-Repeated vaccination could lead to autoimmunity, as excessive antigen exposure overwhelms the immune system's capacity, causing autoimmune tissue damage resembling systemic lupus erythematosus (SLE).

-Increased IgG4 levels induced by repeated vaccination can lead to autoimmune myocarditis, potentially resulting in sudden cardiac deaths.

These negative outcomes may not affect everyone who receives mRNA vaccines, but individuals with genetic susceptibility, immune deficiencies, or co-morbidities may be more likely to experience them. Given the less pathogenic nature of Omicron subvariants and the lack of protection against re-infection offered by mRNA vaccines, clinicians should be cautious when administering boosters due to potential detrimental effects on the immune system.
.
 

Heliobas Disciple

TB Fanatic
The newer study referred to above:

(fair use applies)


IgG4 Antibodies Induced by mRNA Vaccines Generate Immune Tolerance to SARS-CoV-2’spike Protein by Suppressing the Immune System

Vladimir N. Uversky, Elrashdy M. Redwan, William Makis, Alberto Rubio-Casillas
Version 1 : Received: 25 March 2023 / Approved: 27 March 2023 / Online: 27 March 2023 (03:56:26 CEST)

How to cite: Uversky, V.N.; Redwan, E.M.; Makis, W.; Rubio-Casillas, A. IgG4 Antibodies Induced by mRNA Vaccines Generate Immune Tolerance to SARS-CoV-2’spike Protein by Suppressing the Immune System. Preprints 2023, 2023030441. IgG4 Antibodies Induced by mRNA Vaccines Generate Immune Tolerance to SARS-CoV-2’spike Protein by Suppressing the Immune System. Uversky, V.N.; Redwan, E.M.; Makis, W.; Rubio-Casillas, A. IgG4 Antibodies Induced by mRNA Vaccines Generate Immune Tolerance to SARS-CoV-2’spike Protein by Suppressing the Immune System. Preprints 2023, 2023030441. IgG4 Antibodies Induced by mRNA Vaccines Generate Immune Tolerance to SARS-CoV-2’spike Protein by Suppressing the Immune System.



Abstract

Due to the health crisis caused by SARS-CoV-2, the creation of a new vaccine platform based on mRNA was implemented. Globally, around 13.32 billion COVID-19 vaccine doses of diverse platforms have been given, and up to this date, 69.7% of the total population received at least one injection of a COVID-19 vaccine. Although these vaccines prevent hospitalization and severe forms of the disease, increasing evidence has shown they do not produce sterilizing immunity, allowing people to suffer frequent re-infections. Recent research has also raised concerns that mRNA vaccines could induce immune tolerance, which, added to that caused by the virus itself, could complicate the clinical course of a COVID-19 infection. Furthermore, recent investigations have found high IgG4 levels in people who were administered two or more injections of mRNA vaccines. It has been suggested that an increase in IgG4 levels could have a protecting role by preventing immune over-activation, similar to that occurring during successful allergen-specific immunotherapy by inhibiting IgE-induced effects. Altogether, evidence suggests that the reported increase in the IgG4 levels detected after repeated vaccination with the mRNA vaccines is not a protective mechanism; rather, it may be a part of the immune tolerance mechanism to the spike protein that could promote unopposed SARS-CoV2 infection and replication by suppressing natural antiviral responses. IgG4-induced suppression of the immune system due to repeated vaccination can also cause autoimmune diseases, promotes cancer growth, and autoimmune myocarditis in susceptible individuals.



~~~~~~~~~~


And here's Robert Malone talking about it too:


Immune Imprinting: These Vaccines Are Making the Situation Worse - Dr. Robert Malone
2 min 18 sec
 

psychgirl

Has No Life - Lives on TB
The nasal spray I have is called “CofixRx”
You use is when you’re going to be in groups of people or large settings as a prevention.

It kills the virus while still in the nasal passages, preventing infection from taking hold.
 

psychgirl

Has No Life - Lives on TB
Ironically, yesterday I mentioned the past posts about Ig4 immune tolerance studies and today it's back in the news. See the links in the quoted text if you want to see what was posted back then.


(fair use applies)


COVID-19 News: IgG4 Antibodies Produced by mRNA Shots Generate Immune Tolerance To SARS-CoV-2’s Spike Protein By Immune System Suppression
Thailand Medical News
March 29, 2023

A new international study has found that IgG4 antibodies produced by mRNA shots generate immune tolerance to SARS-CoV-2’s spike protein by immune system suppression.

As a result of the health crisis caused by SARS-CoV-2, the creation of a new vaccine platform based on mRNA was implemented. Globally, around 13.32 billion COVID-19 vaccine doses of diverse platforms have been given, and up to this date, 69.7% of the total population received at least one injection of a COVID-19 vaccine.

Though these vaccines prevent hospitalization and severe forms of the disease, increasing evidence has shown they do not produce sterilizing immunity, allowing individuals to suffer frequent re-infections.

Alarmingly however, recent research has also raised concerns that mRNA vaccines could induce immune tolerance, which, added to that caused by the virus itself, could complicate the clinical course of a COVID-19 infection.

In addition, recent investigations have found high IgG4 levels in individuals who were administered two or more injections of mRNA vaccines. It has been suggested that an increase in IgG4 levels could have a protecting role by preventing immune over-activation, similar to that occurring during successful allergen-specific immunotherapy by inhibiting IgE-induced effects.

Cumulatively, evidence suggests that the reported increase in the IgG4 levels detected after repeated vaccination with the mRNA vaccines is not a protective mechanism; rather, it may be a part of the immune tolerance mechanism to the spike protein that could promote unopposed SARS-CoV2 infection and replication by suppressing natural antiviral responses.

IgG4- induced suppression of the immune system due to repeated vaccination can also cause autoimmune diseases, promotes cancer growth, and autoimmune myocarditis in susceptible individuals

The study team comprised of scientists from the following entities:

-University of South Florida-USA

-King Abdulaziz University-Saudi Arabia

-City for Scientific Research and Technology Applications-Egypt

-Cross Cancer Institute, Alberta Health Services-Canada

-University of Guadalajara-Mexico

The increase in IgG4 levels observed after mRNA vaccine administration may be attributed to the unique characteristics of the mRNA vaccine platform, such as the high mRNA concentration and the induction of strong and sustained immune responses. This is supported by the fact that anti-S1 IgG4 responses were not observed in individuals who received the adenovirus-based vaccine.

The optimal dose of vaccine antigen is a crucial factor in the development of a robust and effective immune response. While high antigen doses can cause immune exhaustion and tolerance, low antigen doses may result in a suboptimal immune response. Studies have shown that lower vaccine antigen doses can result in more positive T cell responses and better preventive efficiency. Thus, finding the ideal antigen dose for immunoth erapy is crucial to establish a strong and effective immune response.

The study team concluded that the mRNA shots, particularly the mRNA-1273 vaccine, have been found to induce prolonged IgG4 responses in uninfected individuals, which is not observed with other vaccine platforms. The increase in IgG4 levels may be attributed to the unique characteristics of the mRNA vaccine platform, such as high mRNA concentration and sustained immune responses. The optimal vaccine antigen dose is a crucial factor in developing a robust and effective immune response. Lower vaccine antigen doses may result in more positive T cell responses and better preventive efficiency.

The study findings were published on a preprint server and are currently being peer reviewed. IgG4 Antibodies Induced by mRNA Vaccines Generate Immune Tolerance to SARS-CoV-2’spike Protein by Suppressing the Immune System

Numerous recent studies and COVID-19 News coverages have raised concerns about mRNA-based COVID-19 vaccines potentially inducing tolerance against the spike protein. After multiple Pfizer vaccine doses, research has shown an increase in non-neutralizing IgG4 antibodies, which can be both protective and pathogenic. While this increase in IgG4 levels might prevent immune over-reactivity in some cases, it may also lead to unintended negative consequences, such as inhibiting the immune system's ability to detect and attack the virus.

The immune tolerance mechanism induced by mRNA vaccines could have at least six negative unintended consequences:

-Increased vulnerability to re-infection with new Omicron subvariants, potentially causing severe harm or death in individuals with comorbidities or compromised immune systems.

-Temporarily impaired interferon signaling and immune suppression, leaving the individual vulnerable to other pathogens, re-activating latent infections, or allowing uncontrolled growth of cancer cells.

-Enabling SARS-CoV-2 persistence in the host, potentially leading to chronic infections similar to those caused by hepatitis B, HIV, and hepatitis C viruses.

-A combination of immune suppression from both SARS-CoV-2 infection and vaccination may explain autoimmune conditions, cancers, re-infections, and deaths associated with COVID-19 vaccinations.

-Repeated vaccination could lead to autoimmunity, as excessive antigen exposure overwhelms the immune system's capacity, causing autoimmune tissue damage resembling systemic lupus erythematosus (SLE).

-Increased IgG4 levels induced by repeated vaccination can lead to autoimmune myocarditis, potentially resulting in sudden cardiac deaths.

These negative outcomes may not affect everyone who receives mRNA vaccines, but individuals with genetic susceptibility, immune deficiencies, or co-morbidities may be more likely to experience them. Given the less pathogenic nature of Omicron subvariants and the lack of protection against re-infection offered by mRNA vaccines, clinicians should be cautious when administering boosters due to potential detrimental effects on the immune system.
.
This pretty much summarizes the issue in plain, understandable terminology, in my opinion.
 

Heliobas Disciple

TB Fanatic
The nasal spray I have is called “CofixRx”
You use is when you’re going to be in groups of people or large settings as a prevention.

It kills the virus while still in the nasal passages, preventing infection from taking hold.

Thanks. It has both iodine and xylitol. That's a good product!


CofixRX Triple Action Patented Formula combines Povidone-Iodine with Vitamin D3 — another essential ingredient found in seaweed — and Xylitol.

Here's a related video that happened to come out today:

'It's An Outrage' That Nobody Mentioned the Benefits of Virucidal Nose Spray - Dr. Paul Marik
1 min 16 sec

"Where does the virus replicate?" asked Dr. Marik. "In your nose!" he answered. "So if you want to kill the virus, it's simple — use a virucidal nose spray."

Povidone-iodine, 1% solution, "kills the virus in seconds," attests Dr. Marik.

In a study compared to placebo, nasal spray significantly reduced the time of viral shedding, hospitalization rates, and death.

 

Heliobas Disciple

TB Fanatic
(fair use applies)


COVID-19 RNA Hijacking Uncovered: Unlocking the Door to Innovative Treatments
By University of Gothenburg
March 29, 2023

Coronavirus disease (COVID-19) hijacks parts of infected cells’ vital RNA machinery, thereby blocking important functions in the cells. These damaging changes in the RNA can likely be reversed, potentially leading to new drugs against COVID-19, University of Gothenburg researchers show.

Genetic material in the body’s cells consists of DNA, which serves as long-term storage of genetic information. RNA carries this encoded information to the cells for transcription and translation. These processes enable them to make proteins, which perform most intracellular tasks. The cells’ RNA is modifiable to allow the correct transfer of the DNA information to the proteins. In recent years, scientific understanding of the complexity and importance of these RNA modifications has grown.


Drastic impact


It has been shown that RNA modifications take place in various viruses, but exactly how the viruses affect the RNA modification processes when they infect cells is unknown. This study reports that SARS-CoV-2 infection disrupts the RNA modifications, and the extent of these RNA modification changes surprised the researchers.

One of the modifications affected by SARS-CoV-2, known as m6A (a multifaceted regulator of gene expression), is highly important for RNA’s basic functions, including transportation of data to the protein-making parts of the cell, and transcription and translation into amino acids there.

“We were surprised at the extent and drastic scale of m6A RNA modification loss in SARS-CoV-2 infection. We also found that the coronavirus variants have differing effects on m6A levels,” says Tanmoy Mondal, researcher at Sahlgrenska Academy, University of Gothenburg, who led the project.


Potential drug target


The m6A modification is regulated partly by the enzyme METTL3 (the m6A methyltransferase). The study shows that the localization of this enzyme is affected by the infection; that blocking nuclear export proteins in the cell can restore METTL3 to its original localization while corona infection is ongoing; and that this may serve to arrest the progression of the virus. It might then be possible to develop the blocking effect in a new drug against COVID-19.

The study results may provide new clues to why some people have chronic symptoms that persist long after COVID (“Post-COVID Conditions” or “Long COVID”). The infection appears to leave lasting traces in host cells by removing the m6A modification, which can cause persistent COVID-like symptoms, the scientists note.

They conducted their research using various established research models available for studying SARS-CoV-2 infection. Since the studies were implemented in a controlled laboratory environment, more research is required to show how the virus interacts with human cells in real-life situations.

Reference: “Global loss of cellular m6A RNA methylation following infection with different SARS-CoV-2 variants” by Roshan Vaid, Akram Mendez, Ketan Thombare, Rebeca Burgos Panadero, Rémy Robinot, Barbara F Fonseca, Nikhil R Gandasi, Johan Ringlander, Mohammad Hassan Baig, Jae-June Dong, Jae Yong Cho, Björn Reinius, Lisa A Chakrabarti, Kristina Nystrom and Tanmoy Mondal, 1 March 2023, Genome Research.
DOI: 10.1101/gr.276407.121

The research was carried out in collaboration with scientists in France and South Korea. The results of the study are now published in the journal Genome Research.
 

Heliobas Disciple

TB Fanatic
(fair use applies)


COVID-19 or Flu? New Nano-Sensor Delivers Answers in Just 10 Seconds
By American Chemical Society
March 30, 2023

Scientists have developed a device using single-atom-thick nanomaterials capable of simultaneously detecting the presence of viruses causing COVID-19 and the flu. The device offers much lower detection levels and faster results compared to conventional tests. The researchers will present their findings at the ACS Spring 2023 hybrid meeting.

Have a cough, sore throat, and congestion? Any number of respiratory viruses could be responsible. Conventional tests can identify certain likely culprits by relying on chemical reactions, but some researchers want to swap chemistry for electrical changes sensed by nanomaterials. Today, scientists report using a single-atom-thick nanomaterial to build a device that can simultaneously detect the presence of the viruses that cause COVID-19 and the flu — at much lower levels and much more quickly than conventional tests for either.

The researchers will present their results at the spring meeting of the American Chemical Society (ACS). ACS Spring 2023 is a hybrid meeting being held virtually and in-person March 26–30, and features more than 10,000 presentations on a wide range of science topics.

The symptoms of both flu and COVID-19 overlap considerably, making it difficult to distinguish between them, notes Deji Akinwande, Ph.D., who is presenting the work at the meeting.

“When both of these viruses are circulating together as they did earlier this winter, it would be immensely useful to have a sensor that can simultaneously detect whether you have COVID, flu, none of the above, or both,” he says.

Akinwande, who is at The University of Texas at Austin, says that the device he and colleagues are developing could be modified to test for other infections as well.

The group, including Dmitry Kireev, Ph.D., a postdoc in Akinwande’s lab, constructed the COVID-19 and flu sensor using graphene, a single layer of carbon atoms arranged in a hexagonal lattice pattern. Its extreme thinness renders graphene highly sensitive to any electrical changes in its environment. Akinwande and other researchers see enormous potential in using it and other, similar nanomaterials to create sensors for many different applications.

“These ultra-thin nanomaterials generally hold the record for best sensitivity, even down to the detection of single atoms, and they can improve the ability to detect very small quantities of basically anything that needs to be sensed, whether it’s bacteria or viruses, in gas or in blood,” Akinwande says.

Previously, his group reported designing a graphene-based temporary tattoo that could monitor blood pressure. The tattoo consists of pairs of sensors placed along the arteries of the arm. One half of each pair sends out an electrical current that its partner detects. This signal is used to determine blood flow.

To build the infection sensor, the researchers had to make graphene respond to the presence of viral protein. To do so, they looked to the immune system, which produces antibodies that are fine-tuned to recognize and latch onto particular pathogens. The researchers linked antibodies against SARS-CoV-2, the virus that causes COVID-19, and against the flu virus to graphene. When a sample from an infected person is placed on the sensor, these antibodies bind to their target proteins, prompting a change in the electrical current.

The researchers did not have the safety facilities needed to use whole, active flu or SARS-CoV-2 viruses to test the roughly square-inch sensor. To substitute, they used proteins from these viruses delivered in fluid intended to resemble saliva. Their results indicated that not only could the sensor detect the presence of the proteins, it could do so when they were present at extremely low quantities. This sensitivity suggested the sensor could be used for detecting the much more sparse viral particles found in breath, Akinwande says.

The sensor also worked quickly, returning results within about 10 seconds of dropping in a sample, he says. By comparison, conventional COVID-19 tests can take minutes or hours, depending on the type, and a dual COVID and flu test recently authorized by the U.S. Food and Drug Administration takes about half an hour to produce results.

Akinwande and his group are working to improve its performance further, including by expanding the slate of viruses it can detect. With funding from the National Science Foundation, they are developing a sensor designed to test for SARS-CoV-2 variants, such as omicron and delta. While they are currently focusing on a two-variant design, the test could be adapted to simultaneously identify even more, they say.

The researchers acknowledge support and funding from the National Science Foundation.

Meeting: ACS Spring 2023
Title
Unconventional applications of 2D materials from memory devices to Covid sensors and wearable health

Abstract
This talk will present our latest research findings on 2D nanomaterials towards greater scientific understanding and advanced engineering applications. In particular, the talk will highlight our work on zero-power devices, single-atom monolayer memory and applications, Covid diagnostic sensors and wearable tattoo sensors for mobile health. Non-volatile memory devices based on 2D materials are an application of defects and is a rapidly advancing field with rich physics that can be attributed to metal adsorption into vacancies. The memory devices can be used for neuromorphic computing and operate as communication switches up to 500GHz. Likewise, from a practical point, electronic tattoos based on graphene have ushered a new material platform that has highly desirable practical attributes including optical transparency, mechanical imperceptibility, and is the thinnest conductive electrode sensor that can be integrated on skin for physiological measurements including blood pressure monitoring with clinical accuracy. Most recently, significant progress has been made with 2D materials for rapid Covid diagnostic sensors.
 

Heliobas Disciple

TB Fanatic
(fair use applies)


COVID-19 News: South Australia Facing A New SARS-CoV-2 Onslaught By The Deltacron XBC.1.6 Sublineage
Thailand Medical News
March 30, 2023

Daily COVID-19 infections are rising once again in the state of South Australia that has a population of about 1.77 million individuals.

In the week ending 24th of March 2023, there was 2,888 officially reported new COVID-19 infections out of about 8750 PCR tests conducted.


Local physicians are doubting the figures reported as clinics and hospitals are seeing a rise of people with symptoms and some speculate that the actual numbers could be anything between 3 to 4- fold.

It is being reported that the onslaught is serious as both hospital and ambulance services are being overstretched due to the rising daily caseloads.

According to leading virologists, biostatisticians and variant hunters, the SARS-CoV-2 Deltacron XBC1.1.6 sublineages is leading this new onslaught in South Australia.

View: https://twitter.com/Mike_Honey_/status/1641193698947125248


The Deltracon XBC.1.6 sub-lineage has already reached more that 30% of all sequences submitted from South Australia and the new sub-lineage seems to be having a growth advantage.

The XBC.1.6. sub-lineage is actually a lineage of a recombinant strain of the Delta and Omicron variant.


According to a leading Australian virologist known online as Mike Honey, the ‘grandparent’ XBC variant was a recombinant of BA.2 Omicron and B.1.617.2 Delta, with a presumed origin in the Philippines in August 2022. (Recombinant with the Spike and most of orf1ab from Omicron the rest from Delta)

It's ‘child’ lineage XBC.1 was moderately successful around the world, but never dominant anywhere else. In Australia, it's main reservoir was in Western Australia, where it was around 20-30% for many months. Then the XBC.1.6 variant spawned in South Australia in January, adding Spike R346S and L452R mutations, and many other unique mutations.


Accordingly, the Australian environment/settings at this point seem likely to continue to generate new variants. Immunocompromised individuals there are effectively forced into multiple infections, as masks and other protections are dropped in many healthcare settings. They are more likely to suffer the long chronic infections that are most likely to give the virus time to mutate and try new combinations.

The XBC.1 sub-lineage is defined by two spike mutations S:R346S S:L>M452R and three NSPs mutations: NSP2_A510V, NSP3_C296F,NSP3_H1841Y.

The XBC.1.6 and other arising main sub-lineages are defined by the mutations Orf8:P36L or Orf1b:N498I and another by M:S4F.

View: https://twitter.com/siamosolocani/status/1641218507600719877


Since mid of March, COVID-19 News coverages has highlighted the start of a new onslaught in South Australia.


Despite the rising caseloads in South Australia and overwhelmed hospitals, health authorities have done little to impose any new preventive measures and the general public do not seem fazed by the increase in caseloads despite rising cases of disease severity.

What is more worrisome is the XBC.1.6 sub-lineage could end up spreading to the rest of the states in Australia and also to other countries in a matter of time.

While the rest of the other states in Australia are also seeing a rise in cases, most of these new infections are caused by the various XBB variants that do not seem to be driving disease severity or hospitalizations so far except for those in the vulnerable groups ie the aged, obese, immunocompromised, those with existing comorbidities and those with certain genetic profiles.

It is expected that in coming weeks, the situation in Australia is expected to worsen and winter in the Southern hemisphere will bring a COVID-19 scenario that Australia has yet to have witnessed in the last three years.

For the latest COVID-19 News, keep on logging to Thailand Medical News.

PS: Please share this article to your loved ones and friends so that they can be prepared for what is coming as those controlling the COVID-19 narratives in conjunction with governments and health authorities around the world along with Google, Facebook, Twitter and mainstream media etc are trying to suppress sites like ours and are even shadow banning all articles on COVID=19 etc as they do not want the public to know that their vaccine initiatives are failing badly and not helping in any way but has rather propelled the virus to mutate even more. If anyone with brains does some due diligence..looking at the current kinetics of the COVID-19 pandemic and the number of variants and sub-lineages that have emerged, we are in the worse position than at the start of the pandemic…and we literally have no effective tools ie monoclonal antibodies, antivirals etc. We are just lucky that most of these new sub-lineages only cause asymptomatic or mild symptomatic infections initially as they are more adapted to disrupt immune responses for better viral persistence but they ultimately will cause not only more Long COVID issues but can also give rise to fatal outcomes later such as heart failures, strokes etc.
 

Heliobas Disciple

TB Fanatic
(fair use applies)


U.S. Military Runs COVID Vaccines, Former Pharma Exec Tells RFK Jr.
The U.S. government’s COVID-19 vaccination effort is a biological weapon project run by the U.S. Department of Defense, according to Alexandra Latypova, a former pharmaceutical research and development executive.

By Suzanne Burdick, Ph.D.
3/30/23

The U.S. government’s COVID-19 vaccination effort is a biological weapon project run by the U.S. Department of Defense (DOD), according to Alexandra Latypova, a former pharmaceutical research and development executive with 25 years of industry experience.

Latypova, who oversaw compliance for more than 60 clinical trials, knows the regulatory standards pharmaceutical companies historically were required to meet before bringing a product to market.

“People misunderstand that this is just another instance of Big Pharma corruption,” she told Robert F. Kennedy, Jr., chairman and chief litigation counsel for Children’s Health Defense, during an episode of “RFK Jr. The Defender Podcast.” “It’s much, much bigger than that.”

Latypova said we have government reports describing the COVID-19 vaccines as a biological weapon. “I have a question to our government,” she said. “What is it that they’re exactly forcing on us?”

The DOD is “fully in charge” of the COVID-19 vaccine clinical trials and the vaccine’s manufacturing and distribution, and it owns the vaccine “until it is injected into a person,” she said.

By creating a “pseudo-legal structure” over time that included Emergency Use Authorization (EUA) and other transaction authority agreements — called OTAs — the U.S. government allowed the military to take over the distribution of vaccines without adhering to historical safety testing guidelines or product recall procedures.

According to Latypova, the notion that the COVID-19 vaccines met regulatory standards for safety and effectiveness was the “biggest lie that was sold to the public.”

“I am describing a very illegal structure that’s made legal on paper,” she said. “It’s unlawful. They — the government — are driving this.”

Kennedy agreed with Latypova and pointed out that OTA was designed to allow the Pentagon to quickly buy weapons and weapons systems without paying attention to any existing regulatory authorities.

Kennedy said:

“What they’ve done is they’ve taken that authority and they’ve applied it to the vaccines so they’re purchasing the vaccines under OTA as a demonstration product.

“It’s all a huge military operation and the involvement of the drug companies is a kind of window dressing.”

The DOD paid the pharmaceutical companies for their brand names so people would think they were getting something from Pfizer or Moderna — but all of the distribution and manufacturing is done by the military, Kennedy said. The pharmaceutical companies were brought in to put their name on it and then to pretend to do clinical trials, he said.

Latypova and Kennedy discussed how the military accomplished this without most workers involved in the production and distribution of the vaccine catching on.

They also discussed how citizens and lawyers might effectively challenge the Pentagon’s COVID-19 vaccination project in the court system.

Watch here: (go to link at top of this post - or you can watch it on Bitchute at this link: )

SASHA LATYPOVA AND RFK, JR. - MILITARIZED HEALTHCARE - CHILDREN'S HEALTH DEFENSE (03/16/23)
1 hr 4 min 58 sec
 

psychgirl

Has No Life - Lives on TB
Thanks. It has both iodine and xylitol. That's a good product!


CofixRX Triple Action Patented Formula combines Povidone-Iodine with Vitamin D3 — another essential ingredient found in seaweed — and Xylitol.

Here's a related video that happened to come out today:

'It's An Outrage' That Nobody Mentioned the Benefits of Virucidal Nose Spray - Dr. Paul Marik
1 min 16 sec

"Where does the virus replicate?" asked Dr. Marik. "In your nose!" he answered. "So if you want to kill the virus, it's simple — use a virucidal nose spray."

Povidone-iodine, 1% solution, "kills the virus in seconds," attests Dr. Marik.

In a study compared to placebo, nasal spray significantly reduced the time of viral shedding, hospitalization rates, and death.

I thought it was the right one, thank you for verifying! The Indian pharmacist said they all use it.
I just haven’t wanted to open it until I felt I HAD to because you can’t find it at just any drugstore
 

Heliobas Disciple

TB Fanatic
(fair use applies)


People with long Covid smell disorders or loss of taste may get relief with an experimental treatment

Erika Edwards and Kristen Dahlgren - NBC News
Fri, March 31, 2023, 7:49 PM EDT

A numbing procedure usually used to treat pain and post-traumatic stress disorder is being tested as a way to restore smell and taste in people with long Covid.

It's called a stellate ganglion block. In the procedure, a doctor uses a temporary, local anesthetic — like what a dentist would give before filling a cavity — and injects it into a specific bundle of nerves called the stellate ganglion on both sides of a person's neck. The nerves are part of the sympathetic nervous system, which controls automatic bodily functions, such as blood pressure, digestion and heart rate.

The area is not known to have any impact on how a person perceives odors, however, leaving some experts skeptical of the approach. Other doctors say they have seen real improvements in patients who either can't smell anything or find previously delicious food and drinks now taste repulsive.

Smell disorders tend to become more common with age, and affect millions of people. As many as 1 out of every 8 people in America over age 40 have some kind of olfactory dysfunction, according to the National Institute on Deafness and Other Communication Disorders.

A survey last year found that about 15% of people with Covid-related olfactory loss still had trouble smelling correctly six months later.

Not many treatments are available for smell disorders. Doctors may try olfactory retraining, in which patients concentrate on sniffing four scents — usually rose, eucalyptus, lemon and clove — twice a day for at least three months. Smell therapy has shown promise in some clinical trials.


Getting smell back

At Cleveland Clinic, doctors are offering stellate ganglion blocks to long Covid patients, with the hope of launching a clinical trial.

Jennifer Henderson, 54, of Franklin, Ohio, got Covid in January 2021 and immediately lost the ability to taste or smell anything. A year later, her senses came back, but were wildly distorted.

She first tried olfactory retraining "religiously" for months, without success. Peanut butter and ranch dressing still smelled like chemicals.

Chicken was the worst, she said. "It tasted like rotting flesh. I had to spit it out."

Finally, in November last year, she received the stellate ganglion block at the Cleveland Clinic. The effect was immediate. She held a fresh cup of coffee up to her nose and burst into tears.

"It was the best smell ever," Henderson said. "I just cried like a baby."

Dr. Christina Shin, a physician specializing in pain management at the Cleveland Clinic, said that nearly every day at least one or two patients are referred to her from the long Covid clinic affiliated with the hospital system for help with their smell and taste.

She has treated roughly 30 long Covid patients with the block. About half get better, she estimates, though the level of improvement varies between 25% and 90%.

Dramatic responses like Henderson's have made the rounds on social media, igniting enthusiasm in long Covid communities. But many doctors are cautious because no one really understands how it works.

Some experts theorize that it may increase blood flow to the brain. Others suggest the block acts as a "reset button" for the sympathetic nervous system.

Some question whether it works at all.

"There is no scientific evidence that this is effective," said Dr. Justin Turner, an associate professor in the department of otolaryngology–head and neck surgery at Vanderbilt University Medical Center in Nashville, Tennessee.

"Given the lack of data suggesting efficacy, it's really hard to advocate for this for patients who have a problem that typically resolves with time," he said.

As many as 80% will recover on their own within about six months, said Dr. Zara Patel, a professor of otolaryngology at Stanford University.

That's because stem cells in the nasal cavity have the ability to turn into brand new olfactory receptor neurons that detect odors.

"Throughout our lifetime, probably every three to four months, each olfactory receptor neuron dies off, and a new olfactory receptor neuron comes in and takes its place," Patel said.

Sometimes those new neurons get confused after they regenerate, leading chicken to smell like rotten flesh, as in Henderson's case.

Distorted smell, called parosmia, isn't just about difficulty during mealtimes. The condition can have a profound and deeply upsetting impact on a person's life.

In 2021, researchers in the United Kingdom surveyed people with Covid-related parosmia. Some worried about the effect it had on how they felt about their children.

"A lot of my maternal bonding feelings for my children are tied up with smell," one woman said in the study.

Some reported that the problem was ruining their sex lives. One person wrote about a partner's "rotten breath." The stench was "unbearable, no matter how hard I tried to put it out of my mind."

Some patients fall into despair.

"I have had many patients crying in my office telling me that the parosmia — not just the smell loss, but the smell change — is destroying their life," said Dr. Nyssa Farrell, an assistant professor of otolaryngology-head & neck surgery at Washington University School of Medicine in St. Louis.

However, she was wary of anecdotes of people getting better after a stellate ganglion block.

"It kind of sounds like voodoo," Farrell said. "I'm a scientist and I don't just believe what people say."

With desperate patients in mind, she started a small study to see if the block would work well enough to justify launching a large, randomized clinical trial that would give the needed evidence.

Among 20 patients with trouble smelling correctly, 10 reported "slight to moderate" improvement after the stellate ganglion block. It wasn't a strong result, but enough to move forward "to see if this is a placebo effect or if this is real," Farrell said.

A larger study is in the planning stages.

A stellate ganglion block is not the only potential remedy under investigation for loss of smell. Patel, of Stanford, ran a study looking at whether an injection of platelet-rich plasma deep into the nasal cavity might help prompt olfactory neurons to form correctly.

The procedure involves drawing the patient's own blood, removing its red and white cells, leaving behind plasma full of platelets and growth factors known to regenerate different types of tissue.

"Hopefully, what platelet-rich plasma is doing," Patel said, is getting those neurons to regenerate in a way "so that the correct signal is sent back to the brain."

Among 26 study participants, those who got the plasma injection were 12 times more likely to report improvements in their smell loss than those who got placebo shots.

Patel is now offering the procedure to all of her patients who have lost smell.


Does smell treatment work?


Excitement for stellate ganglion blocks' potential for treating long Covid ramped up in December 2021 when Dr. Luke Liu, a pain specialist in Anchorage, Alaska, reported the successful treatment of two long Covid patients.

Many of their ongoing symptoms, including muscle pain, fatigue, dizziness, brain fog and loss of smell and taste, improved within a week of getting the injections, he said.

Liu theorizes that a "glitch" in the autonomic nervous system plays an important role in lingering Covid and similar post-viral illnesses.

"In the case of long Covid, that glitch prevents the nervous system, and probably the rest of the body, from healing itself from a viral infection," he suggested. "The stellate ganglion block acts by pushing the reset button to that system. By doing so, it allows the entire system to reboot and become more synchronized and organized."

Liu has treated roughly 300 patients, and says about 65-70% "do really well and don't need any other intervention."

Still, he cautioned, it's too early to call stellate ganglion blocks a cure. About 5% of patients, he said, don't have any lasting improvement. About a third must go back to the clinic every few weeks or months for additional injections.

Henderson, who was treated at the Cleveland Clinic, has had to return three times. Her smell and taste are better, she said, but not back to normal.

"This should be treated as a scientific clue rather than a solution at this point," Liu said, adding that larger studies are needed.


What are the risks of smell treatment?

The bundle of nerves targeted in the block procedure is right next to the carotid arteries, a pair of major vessels that supply blood to the brain. If inserted incorrectly, the medication can disrupt vocal chords and lead to trouble breathing.

The risks drop tremendously when a highly experienced doctor performs the stellate ganglion block, which has been used for decades by pain specialists to treat complex pain syndromes, Ferrell said. She partnered with an anesthesiologist for her studies.

"She does stellate ganglion blocks for a living," Ferrell said. "For her, the risks are very low."

The cost of the procedure varies widely and some insurance companies do not cover the block to treat smell disorders.

Liu said that he charges $500 per block, and is disheartened by anecdotes of other clinics billing their patients thousands of dollars.

"To me, this is taking advantage of people who are suffering."
 

Heliobas Disciple

TB Fanatic
(fair use applies)


India sees 114% rise in Covid-19 deaths, 437% rise in cases in 28 days, Omicron variant XBB.1.16 behind the surge, warns WHO
Neetu Chandra Sharma
18 hours ago

India recorded over 114 per cent rise in Covid-19 deaths and 437 per cent spike in cases in the last 28 days, showed the epidemiological report released by the World Health Organization (WHO) on Friday.

The report states that the South-East Asia Region reported over 27,000 new cases, a 152 per cent increase as compared to the previous 28-day period, with the highest proportional increase observed in India (18,130 versus 3,378 new cases) followed by the Maldives (129 per cent) and Nepal (89 per cent). Similarly, India reported at least 62 new deaths which, means 114 per cent rise with 1 new death per 100,000.

The WHO is monitoring the new Omicron variant XBB.1.16 in India which is believed to be behind the sudden surge of the cases. Dr Maria Van Kerkhove, technical lead for the Covid-19 response at WHO, said that there are about 800 sequences of Omicron variant XBB.1.16 from 22 countries. Most of the sequences are from India and in India XBB.1.16 has replaced the other variants that are in circulation.

“XBB.1.16 is actually very similar in profile to XBB.1.5 (Omicron subvariant). It has one additional mutational mutation in the spike protein, which in lab studies shows increase infectivity, as well as potential increased pathogenicity (property of causing disease). It has been in circulation for a few months,” she said.

Public health experts have said that the symptoms of this new variant are mostly low-grade flu-like. People may experience symptoms in the upper and lower respiratory tract. In terms of upper respiratory tract symptoms, people may experience nasal discharge, a sore throat, a slow-rising fever that lasts for one or two days, and loss of smell.

“In case of these symptoms, it is recommended to get tested for Covid. For lower respiratory tract symptoms, people may suffer from severe bronchitis and cough. This new variant is different from others in the sense that it spreads faster than other variants. However, hospitalization rates are very low and can be managed at home,” said Dr Kuldeep Kumar Grover, head of critical care and pulmonology at CK Birla Hospital.

Grover explained that in recent times, people who have been vaccinated and exposed to natural infection during the last Covid waves are developing strong immunity against the virus, which is called hybrid immunity. In hybrid immunity, the body develops antibodies that help fight against mutations of the virus. It has been seen that Covid cases are rising, but they will not lead to massive hospitalizations because of hybrid immunity. “However, it is recommended to follow Covid-related behaviour during the surge of new variants and influenza. People should wash their hands, wear masks, and avoid social gatherings to prevent the spread of any virus. People with symptoms like cough and cold should avoid meeting people so that the infection is not transmitted to healthy individuals,” said Grover.

India reported a massive rise of 3,095 new cases in the last 24 hours with a daily positivity rate of 2.61 per cent. Concerned over the resurgence of Covid-19 cases in the country, the central government has been taking stock of the situation in the states.

According to the data released by the union health ministry, the weekly positivity in Maharashtra has gone up to 4.58 per cent as on March 24, 2023 from 0.54 per cent in the week ending March 3, 2023. In Gujarat, it has increased to 2.17 per cent from 0.07 per cent. In Kerala, weekly positivity shot up to 4.51 from 1.47 per cent. Karnataka witnessed average weekly positivity rise up to 3.05 per cent from 1.65 per cent while Delhi has seen weekly positivity rise to 4.25 per cent from 0.53 per cent. Similarly, Himachal Pradesh witnessed weekly positivity increase to 7.48 from 1.92 per cent. In Rajasthan, it has increased from 0.12 to 1.62 per cent and Tamil Nadu reported an increase in weekly positivity from 0.46 to 2.40 per cent in the same time period.

At least 22 States/UTs are reporting average daily tests per million (TPM) less than the national average. The central government said that 24 districts in India are reporting more than 10 per cent weekly positivity in the week ending 24th March, 2023, while 43 districts are reporting weekly positivity between 5-10 per cent in the same time period.

“The sudden surge of cases throughout India is being seen. The main reason is the new variant of concern of covid-19. The symptoms are mild but a lot of patients are coming up with superimposed pneumonia. Other common reason is the low coverage of precautionary vaccine among the people which is less than 30 per cent,” said Dr Rahul Sharma, Additional Director, Pulmonology and Critical Care, Fortis Hospital Noida.
 

Heliobas Disciple

TB Fanatic
Looks like Geert got his book issue resolved with Amazon!


(fair use applies)


The Inescapable Immune Escape Pandemic
By Geert Vanden Bossche
March 31, 2023

Nobody Can Conceal The Science That Nature Is Now Desperate To Unveil.

Society in highly vaccinated countries will be caught by surprise.


Geert : “Some of you have been wondering why I’ve become so quiet lately. I’ve been working on my book: “The inescapable immune escape pandemic”. The aim of the book is to unambiguously demonstrate that nothing was more predictable than the detrimental consequences of mass C-19 vaccination during a natural pandemic. I absolutely wanted to document the scientific evidence that makes this statement beyond compelling.”
63efdabda9e5fcbe27c949af_3D_The_inescapable_immune_escape_pandemic_M.png

This book delves into various aspects of the evolutionary consequences stemming from the widespread COVID-19 vaccination program. It stands out by emphasizing the scientific intricacy of population-level interactions between the SARS-CoV-2 virus and the host immune system. These interactions are not only complicated but also varied, depending on the infectiousness of the circulating variant and the type of immunity induced (infection-based versus vaccine-based). The book demonstrates how mass vaccination influences these interactions, transforming a natural pandemic into one characterized by immune escape variants. I caution that the ramifications of this could lead to uncontrollable evolutionary viral dynamics due to insufficient herd immunity and potentially cause a massive rebound effect from the hasty and ill-advised deployment of new vaccine technologies (such as rapid mass vaccination during a pandemic). Additionally, I discuss how the adaptability of the human immune system has postponed the emergence of a more virulent variant, contrary to my initial predictions. While some sections may be challenging to comprehend, if the book aids in understanding the complexity of these issues and highlights nature's superiority over the overconfidence of technocrats, my primary objective for writing will be fulfilled.

✅ The book is already available in EUROPE as a paperback and e-book

the Netherlands and Belgium
Bol.com e-book or paperback
or:
Libris.nl paperback
or:
Amazon.nl e-book or paperback
Amazon.com.be paperback

Germany/Deutschland : Amazon.de e-book or paperback

Italy/Italia : Amazon.it e-book or paperback

Spain/Espana : Amazon.de e-book or paperback

France : Amazon.fr e-book or paperback

United Kingdom : e-book or paperback

✅ And worldwide as a paperback or e-book

Amazon.com : paperback
Barnes & Noble : paperback
for e-book : Bol.com (please use your translate function in your browser)

63efdb08b1eb8b04109edff0_AP_The_inescapable_immune_escape_pandemic_L.jpg
 

Heliobas Disciple

TB Fanatic
(fair use applies)


People with long Covid smell disorders or loss of taste may get relief with an experimental treatment

Erika Edwards and Kristen Dahlgren - NBC News
Fri, March 31, 2023, 7:49 PM EDT

A numbing procedure usually used to treat pain and post-traumatic stress disorder is being tested as a way to restore smell and taste in people with long Covid.

It's called a stellate ganglion block. In the procedure, a doctor uses a temporary, local anesthetic — like what a dentist would give before filling a cavity — and injects it into a specific bundle of nerves called the stellate ganglion on both sides of a person's neck. The nerves are part of the sympathetic nervous system, which controls automatic bodily functions, such as blood pressure, digestion and heart rate.

The area is not known to have any impact on how a person perceives odors, however, leaving some experts skeptical of the approach. Other doctors say they have seen real improvements in patients who either can't smell anything or find previously delicious food and drinks now taste repulsive.

Smell disorders tend to become more common with age, and affect millions of people. As many as 1 out of every 8 people in America over age 40 have some kind of olfactory dysfunction, according to the National Institute on Deafness and Other Communication Disorders.

A survey last year found that about 15% of people with Covid-related olfactory loss still had trouble smelling correctly six months later.

Not many treatments are available for smell disorders. Doctors may try olfactory retraining, in which patients concentrate on sniffing four scents — usually rose, eucalyptus, lemon and clove — twice a day for at least three months. Smell therapy has shown promise in some clinical trials.

Getting smell back​

At Cleveland Clinic, doctors are offering stellate ganglion blocks to long Covid patients, with the hope of launching a clinical trial.

Jennifer Henderson, 54, of Franklin, Ohio, got Covid in January 2021 and immediately lost the ability to taste or smell anything. A year later, her senses came back, but were wildly distorted.

She first tried olfactory retraining "religiously" for months, without success. Peanut butter and ranch dressing still smelled like chemicals.

Chicken was the worst, she said. "It tasted like rotting flesh. I had to spit it out."

Finally, in November last year, she received the stellate ganglion block at the Cleveland Clinic. The effect was immediate. She held a fresh cup of coffee up to her nose and burst into tears.

"It was the best smell ever," Henderson said. "I just cried like a baby."

Dr. Christina Shin, a physician specializing in pain management at the Cleveland Clinic, said that nearly every day at least one or two patients are referred to her from the long Covid clinic affiliated with the hospital system for help with their smell and taste.She has treated roughly 30 long Covid patients with the block. About half get better, she estimates, though the level of improvement varies between 25% and 90%.

Dramatic responses like Henderson's have made the rounds on social media, igniting enthusiasm in long Covid communities. But many doctors are cautious because no one really understands how it works.

Some experts theorize that it may increase blood flow to the brain. Others suggest the block acts as a "reset button" for the sympathetic nervous system.

Some question whether it works at all.

"There is no scientific evidence that this is effective," said Dr. Justin Turner, an associate professor in the department of otolaryngology–head and neck surgery at Vanderbilt University Medical Center in Nashville, Tennessee.

"Given the lack of data suggesting efficacy, it's really hard to advocate for this for patients who have a problem that typically resolves with time," he said.

As many as 80% will recover on their own within about six months, said Dr. Zara Patel, a professor of otolaryngology at Stanford University.

That's because stem cells in the nasal cavity have the ability to turn into brand new olfactory receptor neurons that detect odors.

"Throughout our lifetime, probably every three to four months, each olfactory receptor neuron dies off, and a new olfactory receptor neuron comes in and takes its place," Patel said.

Sometimes those new neurons get confused after they regenerate, leading chicken to smell like rotten flesh, as in Henderson's case.

Distorted smell, called parosmia, isn't just about difficulty during mealtimes. The condition can have a profound and deeply upsetting impact on a person's life.

In 2021, researchers in the United Kingdom surveyed people with Covid-related parosmia. Some worried about the effect it had on how they felt about their children.

"A lot of my maternal bonding feelings for my children are tied up with smell," one woman said in the study.

Some reported that the problem was ruining their sex lives. One person wrote about a partner's "rotten breath." The stench was "unbearable, no matter how hard I tried to put it out of my mind."

Some patients fall into despair.

"I have had many patients crying in my office telling me that the parosmia — not just the smell loss, but the smell change — is destroying their life," said Dr. Nyssa Farrell, an assistant professor of otolaryngology-head & neck surgery at Washington University School of Medicine in St. Louis.

However, she was wary of anecdotes of people getting better after a stellate ganglion block.

"It kind of sounds like voodoo," Farrell said. "I'm a scientist and I don't just believe what people say."

With desperate patients in mind, she started a small study to see if the block would work well enough to justify launching a large, randomized clinical trial that would give the needed evidence.

Among 20 patients with trouble smelling correctly, 10 reported "slight to moderate" improvement after the stellate ganglion block. It wasn't a strong result, but enough to move forward "to see if this is a placebo effect or if this is real," Farrell said.

A larger study is in the planning stages.

A stellate ganglion block is not the only potential remedy under investigation for loss of smell. Patel, of Stanford, ran a study looking at whether an injection of platelet-rich plasma deep into the nasal cavity might help prompt olfactory neurons to form correctly.

The procedure involves drawing the patient's own blood, removing its red and white cells, leaving behind plasma full of platelets and growth factors known to regenerate different types of tissue.

"Hopefully, what platelet-rich plasma is doing," Patel said, is getting those neurons to regenerate in a way "so that the correct signal is sent back to the brain."

Among 26 study participants, those who got the plasma injection were 12 times more likely to report improvements in their smell loss than those who got placebo shots.

Patel is now offering the procedure to all of her patients who have lost smell.

Does smell treatment work?​

Excitement for stellate ganglion blocks' potential for treating long Covid ramped up in December 2021 when Dr. Luke Liu, a pain specialist in Anchorage, Alaska, reported the successful treatment of two long Covid patients.

Many of their ongoing symptoms, including muscle pain, fatigue, dizziness, brain fog and loss of smell and taste, improved within a week of getting the injections, he said.

Liu theorizes that a "glitch" in the autonomic nervous system plays an important role in lingering Covid and similar post-viral illnesses.

"In the case of long Covid, that glitch prevents the nervous system, and probably the rest of the body, from healing itself from a viral infection," he suggested. "The stellate ganglion block acts by pushing the reset button to that system. By doing so, it allows the entire system to reboot and become more synchronized and organized."

Liu has treated roughly 300 patients, and says about 65-70% "do really well and don't need any other intervention."

Still, he cautioned, it's too early to call stellate ganglion blocks a cure. About 5% of patients, he said, don't have any lasting improvement. About a third must go back to the clinic every few weeks or months for additional injections.

Henderson, who was treated at the Cleveland Clinic, has had to return three times. Her smell and taste are better, she said, but not back to normal.

"This should be treated as a scientific clue rather than a solution at this point," Liu said, adding that larger studies are needed.

What are the risks of smell treatment?​

The bundle of nerves targeted in the block procedure is right next to the carotid arteries, a pair of major vessels that supply blood to the brain. If inserted incorrectly, the medication can disrupt vocal chords and lead to trouble breathing.

The risks drop tremendously when a highly experienced doctor performs the stellate ganglion block, which has been used for decades by pain specialists to treat complex pain syndromes, Farrell said. She partnered with an anesthesiologist for her studies.

"She does stellate ganglion blocks for a living," Farrell said. "For her, the risks are very low."

The cost of the procedure varies widely and some insurance companies do not cover the block to treat smell disorders.

Liu said that he charges $500 per block, and is disheartened by anecdotes of other clinics billing their patients thousands of dollars.

"To me, this is taking advantage of people who are suffering."

CORRECTION (April 1, 2023, 11:50 a.m. ET): An earlier version of this article misspelled the name of the assistant professor of otolaryngology-head & neck surgery at Washington University School of Medicine in St. Louis. She is Dr. Nyssa Farrell, not Ferrell.
 

Heliobas Disciple

TB Fanatic
Here's the article:

(fair use applies)


Eat Your Vaccines!… I Mean Vegetables!
… Said Bill Gates

Tom Renz
12 hr ago

I have been talking about gene therapy vaccines being introduced into the food supply without providing people informed consent on my Twitter account (@RenzTom) as well as pushing Missouri HB1169 which is our best bet of stopping this happening. This is a nightmare scenario whereby people’s genetics are potentially altered with “factory foods” without them even knowing.

Let me begin by putting to rest any questions as to whether this can happen. The idea of vaccines in food has been around for a long time & is definitely possible. Here is a great article from the year 2000 with a wonderful picture (look at page 3) of exactly how this would be done in vegetables. Here is an article published in the NIH (you know - by our government) talking about foods “under application” to be genetically modified to become edible vaccines - FROM 2013. Below is a screenshot taken of a Google search for “food as a vaccine” taken on Sunday April 2, 2023 (I’m certain Google will begin hiding search results soon but at the time it returned 456 million results!).


.
The fact that food can be altered to act as a vaccine is not disputable. Which foods and in what ways is more of a question. It is claimed that beef, pork, etc. cannot transfer vaccination from the meat to a the consumer of the meat. At initial glance that would make sense (cow DNA and people DNA is quite different and an mRNA designed for cows would probably not be able to transfer directly to people), but that is NOT the whole story.

You have to remember that the additives in the mRNA vaccines are by no means “proven safe” and we don’t even actually know what all is in these shots. The Lipid NanoParticles (LNPs) appear to be a problem and there have been numerous reports of “other things” some scientists have found in the jabs when they examined them. Ultimately the mRNA jabs still have not undergone long-term testing because long-term testing can take 10-20 years and they have not existed that long so any claims about the safety or efficacy of the stuff that’s in them are garbage at best.

What we do know about the mRNA vaccines is that they do not stop the spread of disease (click here to see) and really do not help in any way with anything. We also do know that these jabs were demonstrated, in vitro, to alter the genetic makeup of some cells and I would say it is incredibly likely that they do the outside the Petri dish. Given that we are now talking about a new level of genetic engineering with unknown effects and no long-term studies, do the potential genetic changes the mRNA injections facilitate pose a long-term risk to humans that ingest the altered food? Before you say no, wouldn’t you prefer it be tested rather than being the subject of the experiment?

So with all that in mind, I think it is fair to ask why they would continue to work on and promote a failed product… let alone expand its usage to another industry (Agriculture). Why would seed companies and other companies, outside of the current manufacturers of the COVID jabs, be so excited to develop a product that has failed associated with Died Suddenly and other terrible side effects?

More importantly than anything else is why would the people pushing to use these unproven technologies be opposed to disclosing what they are doing? The pushback against House Bill 1169 in Missouri is shocking. This bill is 2 pages long (you can read it here) and does not ban anything. All it does is require labeling of products that can alter your genetics, require companies share info on transmissibility of gene altering interventions, and that fully informed consent be given for any vaccine, gene therapy, or medical intervention. So why are the RINOs in Missouri, lead by the Democrats and Republican House Speaker Dean Plocher are trying to slow-walk this bill through committee to prevent it from being approved this session?

The answer is the lobbyists. Big Pharma has no legitimate basis for publicly arguing against an informed consent/disclosure bill so they have tried to get the ag lobby to do their dirty work. This is also because the ag bioengineers and big pharma are one and the same. Bayer (big pharma) owns Monsanto which is one of the largest (possibly still the largest) seed producers in the world. Bayer also just happens to be headquartered in Saint Louis, Missouri. Big pharma DOES NOT WANT people to know they are going to use food to alter their genetics.

They also do not want farmers to know they are setting them up. The lobbyists opposing this bill (see below) are pushing to shut this bill down because factory mega-farmers like Bill Gates (see here), the CCP, and others want to put vaccines in your food. These guys are supporting the big money but this will come at the expense of the family farmers. The problem is that the major factory-farmers like Gates have legal teams that can set up defense shields against the torts that may come if the food supply starts poisoning people (I can explain how to do this but will not do so here… I don’t think Gates needs more help). Meanwhile, the small farmers will be at risk of being sued if it turns out that the food they are selling is unsafe despite the fact that most of them will not necessarily know what is happening. If the corn growers, soybean, cattle, and pork associations actually cared about the farmers they would be demanding the seed companies and vaccine manufacturers indemnify the small farmers for these products rather than opposing a bill that would force them to tell the farmers what they are doing.

The corruption regarding this bill is amazing. Ultimately the labeling requirement would likely serve to protect farmers from being sued because the makers of seed and vaccines would have to make sure the farmers knew if they were putting potential gene therapies into their products. The opposition from the ag lobby is not to help the farmers, it is to help their own pockets.

We ALL need to fight back on this. If this bill passes in one state the requirements it imposes would help to protect the food supply of the entire country. That is why this bill is so opposed. This two page bill could help keep people safe but, in the words of one of the committee members from the Missouri Emerging Issues Committee - who cares if they put mRNA in the food? Well, we the people care and we need to let these Dems and sellout RINOs how much we do. Thank Holly Jones for sponsoring this and thank Committee Chair Hardwick for a fair hearing on it. Now it’s time for Speaker Dean Plocher to decide whether he wants to push this through this session (which he absolutely can do) or if he wants to be the RINO that put Missouri farmers at risk of lawsuits and the people of Missouri at risk of having an unsafe food supply.
 

Heliobas Disciple

TB Fanatic
(fair use applies)


Common Childhood Viruses Linked to Severe Hepatitis Outbreak
By University of California - San Francisco
April 2, 2023

A recent study led by researchers at UC San Francisco is making progress in uncovering the reasons behind a puzzling outbreak of acute severe hepatitis in healthy children that emerged in the spring of 2022, following the easing of COVID-19 lockdowns in 35 countries, including the United States.

The occurrence of pediatric hepatitis is uncommon and doctors were alarmed when they began to observe unexplained severe outbreaks. To date, approximately 1,000 cases have been reported, with 50 of these children requiring liver transplants and a minimum of 22 resulting in death.

In the study, published on March 30 in Nature, researchers linked the disease to co-infections from multiple common viruses, in particular a strain of adeno-associated virus type 2 (AAV2). AAVs are not known to cause hepatitis on their own. They need “helper” viruses, such as adenoviruses that cause colds and flu, to replicate in the liver.

Once they returned to school, children were more susceptible to infections with these common pathogens. The study suggests that for a small subset of these children, getting more than one infection at the same time may have made them more vulnerable to severe hepatitis.

“We were surprised by the fact that the infections we detected in these children were caused not by an unusual, emerging virus, but by common childhood viral pathogens,” said Charles Chiu, MD, Ph.D., professor of laboratory medicine and medicine in the Division of Infectious Diseases, director of the UCSF Clinical Microbiology Laboratory, and senior author of the paper.

“That’s what led us to speculate that the timing of the outbreak was probably related to the really unusual situations we were going through with COVID-19-related school and daycare closures and social restrictions,” Chiu said. “It may have been an unintended consequence of what we have experienced during the last two-to-three years of the pandemic.”

By August 2022, clusters of cases were reported in 35 countries, including the U. S., where 358 cases were under investigation. The Centers for Disease Control and Prevention (CDC) launched an investigation into the causes.
Testing for Viruses

To conduct the study, which was backed by the CDC, researchers used polymerase chain reaction (PCR) along with various metagenomic sequencing and molecular-testing methods to examine plasma, whole blood, nasal swab and stool samples from 16 pediatric cases in six states — Alabama, California, Florida, Illinois, North Carolina, and South Dakota — from Oct. 1, 2021, to May 22, 2022. The specimens were compared with 113 control samples.

In genotyping the 14 available blood samples, adeno-associated virus 2 (AAV2) was detected in 93% of the cases and human adenoviruses (HAdVs) were found in all the cases; a specific type of adenovirus linked to gastroenteritis (HAdV-41) was found in 11 cases. Additional co-infections with Epstein-Barr, herpes, and enterovirus were found in 85.7% of cases.

Chiu noted the results mirrored the findings of two concurrent studies conducted in the United Kingdom, which identified the same AAV2 strain. All three studies identified co-infections from multiple viruses, and 75% of the children in the U.S. study had three or four viral infections.

Since AAVs are not considered pathogenic on their own, a direct causal link with severe acute hepatitis has yet to be established. The study notes, however, that children may be especially vulnerable to more severe hepatitis triggered by co-infections. While infections from adeno-associated viruses can occur at any age, the peak is typically between 1 and 5 years old, and the median age of the affected children in the study was 3 years old.

The clusters of acute severe hepatitis in children have recently waned, but Chiu said the best way to protect children from this unlikely outcome is by washing hands frequently and staying home when sick.

Reference: “Adeno-associated virus type 2 in US children with acute severe hepatitis” by Venice Servellita, Alicia Sotomayor Gonzalez, Daryl M. Lamson, Abiodun Foresythe, Hee Jae Huh, Adam L. Bazinet, Nicholas H. Bergman, Robert L. Bull, Karla Y. Garcia, Jennifer S. Goodrich, Sean P. Lovett, Kisha Parker, Diana Radune, April Hatada, Chao-Yang Pan, Kyle Rizzo, J. Bradford Bertumen, Christina Morales, Paul E. Oluniyi, Jenny Nguyen, Jessica Tan, Doug Stryke, Rayah Jaber, Matthew T. Leslie, Zin Lyons, Hayden D. Hedman, Umesh Parashar, Maureen Sullivan, Kelly Wroblewski, M. Steven Oberste, Jacqueline E. Tate, Julia M. Baker, David Sugerman, Caelin Potts, Xiaoyan Lu, Preeti Chhabra, Pediatric Hepatitis of Unknown Etiology Working Group, L. Amanda Ingram, Henry Shiau, William Britt, Luz Helena Gutierrez Sanchez, Caroline Ciric, Christina A. Rostad, Jan Vinjé, Hannah L. Kirking, Debra A. Wadford, R. Taylor Raborn, Kirsten St. George and Charles Y. Chiu, 30 March 2023, Nature.
DOI: 10.1038/s41586-023-05949-1

The study was funded by the Biomedical Advanced Research and Development Authority, the National Institute of Child Health and Human Development, and the U.S. Centers for Disease Control and Prevention.
 

Heliobas Disciple

TB Fanatic
(fair use applies)


Do COVID-19 Monoclonal Antibody Treatments Really Work? What Two Years of Patient Data Reveal

By University of Pittsburgh
April 3, 2023

The COVID-19 pandemic necessitated rapid deployment of monoclonal antibody treatments at a scale never seen before. A new study published in the Annals of Internal Medicine confirmed the value of these efforts. Analyzing one of the largest US databases of patients treated with monoclonal antibodies, researchers found that treatment within two days of a positive COVID-19 test reduced the risk of hospitalization or death by 39% compared to untreated peers. This risk reduction was even greater for immunocompromised patients. The study highlights the importance of investing in infrastructure and healthcare worker knowledge to deliver antibody treatments quickly, especially in the face of potential future deadly virus variants.

A study by UPMC and the University of Pittsburgh School of Medicine found that monoclonal antibody treatments significantly reduced the risk of hospitalization or death from COVID-19. The research underscores the importance of investing in infrastructure and healthcare professional skills to efficiently deliver these treatments, particularly in case of more lethal virus variants emerging in the future.

The COVID-19 pandemic created a real-life experiment that demanded health care providers nationwide rapidly stand up clinics to administer an evolving offering of monoclonal antibody treatments that — while initially proven safe and effective in clinical trials and approved under federal emergency use authorization — had never been tested at such a scale.

The task was massive and the real-world benefit was uncertain, particularly for monoclonals approved later in the pandemic based only on laboratory data. An analysis published today (April 3, 2023) in the Annals of Internal Medicine by UPMC and University of Pittsburgh School of Medicine clinicians and scientists shows that it was worth it.

“The virus was a moving target, and, for two years, monoclonal antibodies were approved, revoked, sometimes reauthorized, and sometimes scarce,” said lead author Kevin Kip, Ph.D., vice president of clinical analytics at UPMC. “Using UPMC’s database of patients treated with monoclonal antibodies —one of the largest in the U.S. — we are finally able to conclude that pushing through all these challenges unequivocally saved lives and prevented hospitalizations.”

Monoclonal antibodies are human-made antibodies specifically designed to prevent a pathogen — in this case, the virus that causes COVID-19 — from entering human cells, replicating, and causing serious illness. The U.S. Food and Drug Administration granted emergency use authorization to five different COVID-19 monoclonal antibody treatments at various times between 2020 and 2022. All were restricted to people aged 12 and older with risk factors that made them more susceptible to bad outcomes from COVID-19. The treatments had to be administered intravenously or through injection by a healthcare professional. As the virus evolved, new monoclonal antibodies were introduced and older ones, which were no longer effective, were removed.

Starting with the first authorization at the end of 2020, UPMC opened dozens of clinics, set up emergency department infrastructure, and arranged home visits to maximize its ability to provide monoclonal antibodies to patients in Pennsylvania, New York, and Maryland. After the emergency use authorization was revoked for the last monoclonal antibody on November 30, 2022, and no new monoclonal antibodies were introduced, UPMC pulled anonymous clinical data on 2,571 patients treated with monoclonal antibodies and matched them with data from 5,135 patients with COVID-19 who were eligible for monoclonal antibodies but did not receive them.

On average, people who received monoclonal antibodies within two days of a positive COVID-19 test reduced their risk of hospitalization or death by 39% compared to their peers who did not receive the treatment. Patients with immunocompromising conditions, regardless of their age, had an even greater reduced risk.

Patients treated when the alpha and delta variants of the virus were circulating experienced greater benefit than their untreated peers compared to those treated when the omicron variant was circulating, likely because earlier variants were more deadly and people had less prior immunity from previous infection or vaccination. By the time omicron was circulating, risk of death and hospitalization had fallen in general, so monoclonal antibody treatment had less overall benefit, but still clinically meaningful benefit, particularly in vulnerable patients, explained co-author Erin McCreary, Pharm.D., director of infectious diseases improvement and clinical research innovation at UPMC.

“Right now, COVID-19 has a relatively low risk of death for the general population, but we have seen how quickly this virus can mutate and spread. Nobody can say with certainty that a future variant won’t be more deadly,” McCreary said. “Should that happen, our real-world data give reassurance that investing in the infrastructure and healthcare worker knowledge to quickly give antibody treatments keeps people in the communities we serve alive and out of the hospital.”

Reference: “Evolving Real-World Effectiveness of Monoclonal Antibodies for Treatment of COVID-19” 3 April 2023, Annals of Internal Medicine.
DOI: 10.7326/M22-1286

Additional authors on this research are Kevin Collins, M.B.A., Tami E. Minnier, M.S., Graham M. Snyder, M.D., M.S., William Garrard, Ph.D., Jeffrey C. McKibben, M.S., Donald M. Yealy, M.D., Christopher W. Seymour, M.D., M.S., David T. Huang, M.D., M.P.H., J. Ryan Bariola, M.D., Mark Schmidhofer, M.D., Richard J. Wadas, M.D., Derek C. Angus, M.D., M.P.H., Paula L. Kip, Ph.D., and Oscar C. Marroquin, M.D., all of UPMC, Pitt or both.
 

Zoner

Veteran Member
Looks like Dr. Malone is not our friend.

View: https://twitter.com/RealDrJaneRuby/status/1643285295885058049?s=20


View: https://twitter.com/RealDrJaneRuby/status/1643252082160332806?s=20



 
Last edited:

Heliobas Disciple

TB Fanatic
(fair use applies)


New study shows SARS-CoV-2 infection accelerates the progression of dementia
by IOS Press
April 4, 2023


new-study-shows-sars-c-1.jpg

The possible common pathomechanisms linking multiple sclerosis and post-COVID-19 brain involvement (A). Proposal of a new codename regarding post-COVID-19 cognitive sequelae (B). Credit: Journal of Alzheimer's Disease Reports (2023). DOI: 10.3233/ADR-220090


Infection with SARS-CoV-2 has a significant impact on cognitive function in patients with preexisting dementia, according to new research published in the Journal of Alzheimer's Disease Reports. Patients with all subtypes of dementia included in the study experienced rapidly progressive dementia following infection with SARS-CoV-2.

Since the first wave of COVID-19, neurologists have noticed both acute and long-term neurological syndromes and neuropsychiatric sequelae of this infectious disease. Insights into the impact of COVID-19 on human cognition has so far remained unclear, with neurologists referring to "brain fog."

A group of researchers driven to gain a better understanding of and dissipate this fog investigated the effects of COVID-19 on cognitive impairment in 14 patients with preexisting dementia (four with Alzheimer's disease [AD], five with vascular dementia, three with Parkinson's disease dementia, and two with the behavioral variant of frontotemporal dementia), who had suffered further cognitive deterioration following COVID-19.

Lead investigators Souvik Dubey, MD, DM, from the Department of Neuromedicine, Bangur Institute of Neurosciences (BIN), Kolkata, West Bengal, India, and Julián Benito-León, MD, Ph.D., from the Department of Neurology, University Hospital "12 de Octubre," Madrid, Spain, explained, "We speculated there must have been some deleterious effect of COVID-19 in patients with preexisting dementia extrapolating our understanding from the cognitive impact of this viral infection in patients without dementia. However, post-COVID-19 evaluation of cognitive impairments in patients with preexisting dementia is difficult due to multiple confounders and biases."

In addition to finding that that all subtypes of dementia, irrespective of patients' previous dementia types, behaved like rapidly progressive dementia following COVID-19, the team of investigators found that the line of demarcation between different types of dementia became remarkably blurry post-COVID-19.

Co-investigator Ritwik Ghosh, MD, Department of General Medicine, Burdwan Medical College and Hospital, Burdwan, West Bengal, India, expressed his concern about dementia subtyping. "It is more difficult in the post-COVID-19 era, where the history of this viral infection plays the most important role. Few patients with a history of COVID-19 without preexisting dementia have phenotypically and imaging-wise similar brain changes mimicking other degenerative and vascular dementias."

Researchers also found that the characteristics of a particular type of dementia changed following COVID-19, and both degenerative and vascular dementias started behaving like mixed dementia both clinically and radiologically. A rapidly and aggressively deteriorating course was observed in patients having insidious onset, slowly progressive dementia, and who were previously cognitively stable.

Cortical atrophy was also evident in the study's subsequent follow-ups. Coagulopathy involving small vessels and inflammation, which were further correlated with white matter intensity changes in the brain, was considered the most important pathogenetic indicator.

The rapid progression of dementia, the addition of further impairments/deterioration of cognitive abilities, and the increase or new appearance of white matter lesions suggest that previously compromised brains have little defense to withstand a new insult (i.e., a "second hit" like infection/dysregulated immune response and inflammation).

According to Dr. Dubey and his co-investigators, "'Brain fog' is an ambiguous terminology without specific attribution to the spectrum of post-COVID-19 cognitive sequelae. Based on the progression of cognitive deficits and the association with white matter intensity changes, we propose a new term: 'FADE-IN MEMORY' (i.e., Fatigue, decreased Fluency, Attention deficit, Depression, Executive dysfunction, slowed INformation processing speed, and subcortical MEMORY impairment)."

Co-investigator Mahua Jana Dubey, MD, Department of Psychiatry, Berhampur Mental Hospital, Berhampur, West Bengal, India, added, "Amidst various psychosocial impacts of COVID-19, cognitive deficits, when accompanied by depression and/or apathy and fatigue in patients with or without preexisting dementia, require meticulous evaluation because it imposes added stress and burden on caregivers, one of the most important but often forgotten issues that may have the potential to hamper treatment."

"As the aging population and dementia are increasing globally, we believe pattern recognition of COVID-19-associated cognitive deficits is urgently needed to distinguish between COVID-19-associated cognitive impairments per se and other types of dementia. This understanding will have a definitive impact on future dementia research," Dr. Souvik Dubey concluded.

"Increasing epidemiological evidence of the association of COVID-19 and AD is the heightened risk of AD with COVID-19, and of increased COVID-19 in patients with AD points to shared pathogenesis. Dubey et al further clarify this connection in demonstrating COVID-19 fundamentally alters the course of dementia no matter the cause," remarked George Perry, Ph.D., Editor-in-Chief, Journal of Alzheimer's Disease, and Semmes Distinguished University Chair in Neurobiology at The University of Texas at San Antonio.

More information: Souvik Dubey et al, The Effects of SARS-CoV-2 Infection on the Cognitive Functioning of Patients with Pre-Existing Dementia, Journal of Alzheimer's Disease Reports (2023). DOI: 10.3233/ADR-220090
 

Heliobas Disciple

TB Fanatic
(fair use applies)


Gilead details promising early COVID antiviral data, setting up larger studies

Deena Beasley
Tue, April 4, 2023, 6:34 PM EDT·

(Reuters) - Gilead Sciences Inc on Tuesday unveiled data from the first human study of its experimental oral COVID-19 antiviral, saying the results in healthy volunteers cleared the way for two large Phase III trials of the drug that have begun enrolling patients.

The drug, obeldesivir and previously known as GS-5245, is designed to keep the coronavirus that causes COVID from replicating in the body and overwhelming a patient's immune system. Once metabolized, it works in the same way as Gilead's older intravenous COVID treatment Veklury (remdesivir), which targets virus replication through inhibition of the viral RNA polymerase.

For standard risk patients, Gilead believes the new drug could help resolve symptoms earlier and is evaluating any association with symptoms of long COVID, Anu Osinusi, who oversees clinical research for hepatitis, respiratory and emerging viruses at Gilead, told Reuters.

"The WHO still calls this a global health emergency ... We are not seeing a surge, but the numbers are holding steady," she said of the World Health Organization.

The Phase I trial, which involved 70 healthy adults, showed that obeldesivir reached sufficient concentrations in the blood and supports taking it without regard to food, according to Gilead.

Two obeldesivir patients reported headache, as did one placebo patient. No serious side effects were reported.

The most common laboratory abnormality was grade 2 creatinine clearance decrease, which can be an indication of impaired kidney function and occurred in 31% of treated participants and 25% of placebo participants.

Gilead has advanced obeldesivir into two late-stage global studies for treating non-hospitalized COVID patients. One trial is enrolling vaccinated people with at least two risk factors for developing serious COVID and unvaccinated patients with at least one risk factor.

The other is enrolling COVID patients at standard risk of serious illness regardless of vaccination status.

Osinusi declined to comment on timing of results from the Phase III trials, noting that progress will depend on the course of the pandemic.

The dosing regimen for both studies is a twice-daily tablet for five days, which would be a big advantage over currently available oral COVID antivirals if obeldesivir is proven to be effective.

Pfizer Inc's Paxlovid consists of three pills taken twice a day for five days, while Merck & Co's Lagevrio is four capsules taken twice a day for five days.

Paxlovid also can interact with a large number of medications, forcing patients to temporarily go off their other medicines or doctors to refrain from prescribing it for some. Lagevrio was shown in clinical trials to be less effective than Paxlovid in separate studies.

Gilead's data is being presented later this month at the European Congress of Clinical Microbiology & Infectious Diseases in Copenhagen.
 

Heliobas Disciple

TB Fanatic
I am posting this to document that in the winter of 2023, they are still publishing articles like this in the MSM. :mad:


(fair use applies)

Fact check: COVID-19 vaccines are safe during pregnancy, contrary to viral claim
Isabella Fertel, USA TODAY
Tue, April 4, 2023, 5:42 PM EDT


The claim: Posts imply miscarriages and stillbirths drastically increased in 2021 due to COVID-19 vaccines​

A March 23 Instagram post (direct link, archived link) features a graph showing an apparent spike in miscarriages and stillbirths in 2021 and 2022.

“Miscarriage/stillbirth by year….probably climate change #fauciforprison,” reads the post's caption.

Some social media users took this graph as evidence that COVID-19 vaccines are behind the apparent uptick in miscarriages and stillbirths.

“COVID-19 VAX is what’s goin’ on,” wrote one commenter. “Or should I say WENT IN.”

The post garnered more than 1,600 likes in less than two weeks. Several other versions of the post have circulated on Instagram and Twitter since October 2022.

Our rating: Missing context


The implied claim here is wrong. The graph is based on data from the Vaccine Adverse Event Reporting System that is unverified and cannot determine if a vaccine caused a particular outcome. Scientists say a growing body of evidence shows COVID-19 vaccines do not cause an increased risk of miscarriage or stillbirths.

No link between COVID-19 vaccines and miscarriages or stillbirths, scientists say​

Since the release of COVID-19 vaccines, researchers have monitored VAERS as well as two other systems: the COVID-19 Vaccine Pregnancy Registry and the Vaccine Safety Datalink.

"The totality of evidence from these monitoring systems indicates that COVID-19 vaccination during pregnancy is not associated with an increased risk of miscarriage or stillbirth," said Dr. Tom Shimabukuro, director of the Centers for Disease Control and Prevention's Immunization Safety Office.

Multiple studies conducted in the U.S. and abroad found no significant safety concerns for pregnant people who received COVID-19 vaccines or their babies.

COVID-19, on the other hand, can have severe consequences in pregnancy.

Researchers have found substantial evidence that pregnant people infected with the COVID-19 virus are more likely to experience certain health complications, including delivering a preterm or stillborn infant.

"COVID-19 vaccination during pregnancy is safe and effective," Shimabukuro said. "There is substantial evidence that vaccination during pregnancy protects pregnant women, protects their pregnancies and protects their developing fetuses."

Graphs misuse unverified reporting system data​

The posts cite their source as VAERS, which is jointly managed by the CDC and the Food and Drug Administration.
VAERS collects reports of possible side effects, or “adverse events,” in people who have recently received vaccinations.
The system was created to detect “unusual or unexpected patterns" of symptoms, which can indicate possible vaccine safety issues.

But the VAERS website states multiple times that reports cannot be interpreted as evidence that a vaccine caused a health problem. Anyone can submit a report, and the system encourages people to report adverse events even if it is not clear the vaccine is related to their symptoms.

Entries in the reporting system are not automatically verified or authenticated, according to Dr. Kawsar Talaat, an associate professor at Johns Hopkins University.

“Just because an event is reported to the system does not necessarily mean the event has anything to do with a recent vaccination,” Talaat said. “If you fall and break your leg after getting a vaccination, you can report it.”

A singular adverse event may also be reported several times in the system due to reporting requirements for vaccine manufacturers and healthcare providers, Talaat said.

The reporting system’s website notes its data is often misinterpreted by the public and states “numbers of reports may increase in response to media attention and increased public awareness.”

VAERS data has been frequently taken out of context and misused since the rollout of COVID-19 vaccines, according to Talaat. USA TODAY has debunked previous attempts to use VAERS data to prove "COVID-vaccine injuries" and COVID-19 vaccine death reports.

The 2021 figure shown in the graph also does not match the current tally in VAERS.

The graph shared with some posts making this claim includes a numerical scale that indicates more than 3,500 miscarriages and stillbirths were reported to the system in 2021. But the database lists about 2,600 reports.

No national data on miscarriages​

Experts say there is no statistic for the aggregate number of miscarriages per year because miscarriages are so common.

Shimabukuro also noted that some miscarriages, especially miscarriages that happen in the early weeks of gestation, are not brought to medical attention.

Miscarriages are relatively common overall, according to Dr. Andrea Sharma, an epidemiologist and maternal health expert at the CDC. She said approximately 10% to 15% of clinically identified pregnancies end before 20 weeks of gestation.

Stillbirths, or the loss of a pregnancy after 20 weeks, are less common. The CDC estimates that 1 in 175 pregnancies in the U.S. is affected by stillbirth. USA TODAY was unable to locate data on stillbirths that covered the 2021 and 2022 period cited in the claim.

USA TODAY reached out to users who shared the post for comment.

Reuters also debunked this claim.

Our fact-check sources:​

Thank you for supporting our journalism. You can subscribe to our print edition, ad-free app or electronic newspaper replica here.

Our fact-check work is supported in part by a grant from Facebook.

This article originally appeared on USA TODAY
: Fact check: COVID-19 vaccines are safe during pregnancy, studies show
 

Heliobas Disciple

TB Fanatic
(fair use applies)


Researchers Discover Connection Between Traumatic Brain Injury and Long COVID
By University of Denver
April 4, 2023

The Linseman Laboratory is studying the long-term brain health effects of COVID-19 in individuals with and without traumatic brain injury (TBI). Preliminary data suggest that those with a history of both COVID-19 and TBI experience more severe long COVID symptoms. The study is also examining blood biomarkers to understand age-related differences in long COVID and explore potential treatments targeting neuroinflammatory pathways.

In January 2021, Ron Miller’s life was upended. The then-39-year-old, who described his health at the time as perfectly fine, contracted COVID-19. Two years later, he’s unable to work as he still suffers from extreme fatigue and brain fog—a byproduct of his battle with long COVID.

Ron’s not alone. In fact, he’s among the nearly 20% of people who’ve experienced lingering COVID-19 symptoms.

The details of the persisting illness, Ron says, are fuzzy. There’s no clear delineation of when the acute symptoms stopped and when the long COVID symptoms began.

“It never really went away,” he says.

Ron, whose name has been changed for this story, is part of the Linseman Laboratory’s study on the long-term brain health effects of COVID-19 in people with and without traumatic brain injury (TBI).

The lab, which is run by University of Denver College of Natural Sciences and Mathematics professor Dan Linseman, is part of the Knoebel Institute for Healthy Aging. The lab’s work focuses on neuroinflammation, neurodegeneration, neurotrauma and now long-neurological COVID.

Allison Grossberg, a fourth-year doctoral student in the cellular and molecular biology program, is leading the study, which began in 2022 and partners with National Jewish Health and Resilience Code. Grossberg and Linseman wanted to know whether individuals with a history of both brain trauma and COVID-19 have worsened long-term neurological and psychological symptoms, increased inflammation, or an increased risk of neurodegenerative disease and/or auto-immunity.

“Certain infections like COVID-19 and Lyme disease can lead to inflammation in the brain—so why should they be any different?” Grossberg says.

So far, the Linseman Lab has preliminary data for 48 of the study’s participants, 28 of whom, like Ron, had COVID-19 and one or more TBIs; 11 had only a TBI; and five had only COVID. And four participants—the control group—had no history of COVID or TBI.

The study collects its data through a yearly visit in which participants complete a cognitive assessment and a detailed questionnaire and have blood drawn.

Linseman and Grossberg say it’s possible the findings may change over the five-year study as more participants are recruited. But as of now, the preliminary data is clear: Those with a history of COVID-19 and TBI reported more severe long COVID symptoms, a higher symptom burden, and more frequent symptoms.

For many of the study’s participants who have had a concussion, including Ron, it’s been decades since their injury.

“Concussions you get when you are young can cause persistent underlying damage, and some of that damage is likely persistent neuroinflammation,” Linseman says. “For example, we found that people who have Lyme disease have a certain cadre of neurological symptoms, but if they have a history of concussions, those symptoms are much worse. I think it’s similar with COVID. These are all neurotropic, so they get into the brain. They cause inflammation. If they do that on a background of sustained persistent neuroinflammation like a history of head injury, it basically becomes a cumulative effect on the brain.”

The study participants ranged in age from 18-83. Everyone who reported contracting COVID-19 had mild to moderate symptoms. Nasal congestion was the most reported, and chest pain and tightness were the most severe.

Those who reported having COVID-19 and TBI reported worse depressive symptoms, worse functional outcomes, and increased fatigue.

The study isn’t only recording information through a unique detailed questionnaire. Grossberg and Linseman are also examining biomarkers from the blood samples of each participant. Every cell in the body secretes lipid vesicles, Grossberg says, which are used to communicate with other cells in the body.

“They’re tagged with little markers that are specific to each cell type that releases them,” Grossberg says. “Inside these little packages are tons of important signaling molecules that help us understand what’s going on in someone’s brain as opposed to just what’s happening in the bloodstream.”

Then researchers can take the vesicles, or exosomes, from each patient and incubate them with cells grown in the lab.

“We expect that the exosomes from participants with history of COVID and TBI carry cargo that might cause an inflammatory response in the cell that is worse compared to exosomes from healthy control participants,” Grossberg says. “We expect it to look similar to the inflammatory response in cells exposed directly to a bacterial endotoxin, a lipopolysaccharide, which is known to cause inflammation,” Grossberg says.

According to the preliminary data, exosomes from those who had a combined history of COVID-19 and TBI caused inflammation in the lab-grown astrocytes.

What’s more, Linseman says, is the potential link between age and long COVID. When the study began, they anticipated that older people with a history of concussions would report the worst long COVID symptoms. So far in their findings, the opposite is true.

“That’s leading me into supporting the theory with the immune system and neuroinflammation that’s contributing to the symptomology,” Linseman says. “The biggest difference between older and younger people is that younger people have a more robust immune system.”

If their hypothesis is correct, and there’s a neuroinflammatory pathway that’s upended by COVID and TBI, researchers can start to explore potential treatments, like one that inhibits the inflammatory pathway.

While that discovery may be years in the making, the Linseman Lab’s study is making strides in the right direction.

For Ron, a DU graduate who was a partner in a risk management consulting firm, participating in this study means something—a tangible way to make an impact.

“If it could be helpful to society overall, not necessarily just me, it would be nice. Who knows if it will keep others from getting it in the future,” Ron says. “I have a lot of time on my hands, might as well use it to contribute some good.”
 

Heliobas Disciple

TB Fanatic
(fair use applies)


Pfizer hid data on waning immunity as millions queued to get vaccinated.
New regulatory filings show Pfizer had evidence, early into the vaccination campaign, that its vaccine’s efficacy waned, but waited months before alerting the public.

Maryanne Demasi, PhD
Apr 5

In late 2020, the airways became saturated with triumphant reporting of Pfizer and Moderna’s “95% effective” covid-19 vaccines. Millions rolled up their sleeves with the belief that reaching herd immunity would end the pandemic.

But by June 2021, the pandemic endgame story had gone off script. Highly vaccinated countries like Israel were experiencing a new wave of covid infections, vaccination rates were starting to slow, and public scepticism was snowballing.

Authorities tried to allay fears by saying that new infections were “rare breakthroughs,” but the data became too difficult to ignore.

By early July, the Israeli Ministry of Health reported that vaccine effectiveness against infection and symptomatic disease had fallen to 64%. Three weeks later, revised estimates put Pfizer’s vaccine at just 39% effective.

Delayed disclosure

Regulatory filings date stamped from April 2021 show Pfizer had strong evidence that its vaccine’s efficacy waned – results the company did not publicly release until the end of July.

Peter Doshi, associate professor at the University of Maryland School of Pharmacy, accessed these documents from the Canadian drug regulator, Health Canada.

“It’s clear from the documents that these analyses were almost four months old by the time they became public,” said Doshi.

“It’s disappointing that neither Pfizer, nor regulators, disclosed these data until it was too obvious to ignore new outbreaks in Israel and Massachusetts, which made it clear that vaccine performance was not holding up.”

When mRNA vaccines were first authorised in 2020, FDA scientists had listed critical ‘gaps’ in the knowledge base. Two of them -- effectiveness against viral transmission and duration of protection.

But on April 1, 2021, when Pfizer announced its 6-month data from its phase III trial, there was no mention of waning immunity by Pfizer or the regulators. On the contrary, officials repeated standard talking points.

Speaking on national TV, Anthony Fauci told the American public that “when you get vaccinated, you not only protect your own health ... you become a dead end to the virus.”

Then, on a door-to-door vaccination drive, Fauci told one unvaccinated resident, “on the very, very, very rare chance that you do get it even if you’re vaccinated … you don’t even feel sick, it’s like you don’t even know you got infected.”

Martin Kulldorff, biostatistician, and professor of medicine at Harvard (on leave) says he is disappointed with the lack of transparency.

“In public health, it is important to be honest with the public. Pfizer should have reported the declining vaccine efficacy in its April 1, 2021 press release, which they clearly knew about at the time,” said Kulldorff.

Pfizer gave no explanation for why it delayed the publication of its data. The FDA did not confirm when it first learned about waning efficacy and Health Canada did not respond by the deadline.

Outcome of hiding data?

In that four-month delay, approximately 90 million Americans queued to get vaccinated (see graph), unaware that data were already in hand, hinting that two doses may not be the final ask.



Doshi speculated that if the public was told about waning efficacy in April 2021, it may have hampered a vaccination campaign that had enormous momentum.

“Publicly disclosing that efficacy waned so soon after authorisation might have undermined the credibility of authorities, who’d been projecting great confidence about the vaccines’ ability to end the pandemic,” said Doshi.

“Also, the safety evaluation was based on a course of two doses, so publishing data that might jumpstart a conversation about people needing extra doses, could certainly have raised questions about vaccine safety,” added Doshi.

Within weeks of Pfizer publishing its data on waning efficacy, President Biden mandated all federal workers (and employees of contractors) to get vaccinated within 75 days, otherwise they’d face punishment or have their employment terminated.
 

Heliobas Disciple

TB Fanatic
(fair use applies)


The Immunity Puzzle: Why Viruses Like COVID-19 Can Reinfect Hosts, Evade the Immune Response
By Brigham and Women's Hospital
April 6, 2023

Using a tool called VirScan, Brigham investigators found that people produced shared antibody responses to certain regions of the virus, likely leading to selective pressure and new variants that can repeatedly escape detection by prior immunity.

The human body is capable of creating a vast, diverse repertoire of antibodies—the Y-shaped sniffer dogs of the immune system that can find and flag foreign invaders. Despite our ability to create a range of antibodies to target viruses, humans create antibodies that target the same viral regions again and again, according to a new study led by investigators from Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, and Harvard Medical School. These “public epitopes” mean that the generation of new antibodies is far from random and that a virus may be able to mutate a single amino acid to reinfect a population of previously immune hosts. The team’s findings, which have implications for our understanding of immunity and public health, will be published today (April 6) in the journal Science.

“Our research may help explain a lot of the patterns we’ve seen during the COVID-19 pandemic, especially in terms of re-infection,” said corresponding author Stephen J. Elledge, PhD, the Gregor Mendel Professor of Genetics at the Brigham and HMS. “Our findings could help inform immune predictions and may change the way people think about immune strategies.”
Antibodies Lysine-Specific GRAB Motif

Before the team’s study, there were hints, but no clear evidence, that people’s immune systems didn’t target sites on a viral protein at random. In isolated examples, investigators had seen recurrent antibody responses across individuals—people recreating antibodies to home in on the same viral protein location (known as an epitope). But the study by Elledge and colleagues helps explain the extent and underlying mechanisms of this phenomenon.

The team used a tool the Elledge lab developed in 2015 called VirScan, which can detect thousands of viral epitopes — sites on viruses that antibodies recognize and bind to — and give a snapshot of a person’s immunological history from a single drop of blood. For the new study, the researchers used VirScan to analyze 569 blood samples from participants in the U.S., Peru, and France. They found that recognition of public epitopes — viral regions recurrently targeted by antibodies — was a general feature of the human antibody response. The team mapped 376 of these commonly targeted epitopes, uncovering exactly where antibodies bind their targets. The team found that antibodies recognized public epitopes through germline-encoded amino acid binding (GRAB) motifs—regions of the antibodies that are particularly good at picking out one specific amino acid. So, instead of randomly choosing a target, human antibodies tend to focus on regions where these amino acids are available for binding, and thus repeatedly bind the same spots.

A small number of mutations can help a virus avoid detection by these shared antibodies, allowing the virus to reinfect populations that were previously immune.

“We find an underlying architecture in the immune system that causes people, no matter where in the world they live, to make essentially the same antibodies that give the virus a very small number of targets to evade in order to reinfect people and continue to expand and further evolve,” said lead author Ellen L. Shrock, PhD, of the Elledge lab.

Interestingly, the team notes that nonhuman species produce antibodies that recognize different public epitopes from those that humans recognize. And, while it is more likely for a person to produce antibodies against a public epitope, some people do produce rarer antibodies, which may more effectively protect them from reinfection. These insights could have important implications for treatments developed against COVID-19, such as monoclonal antibodies, as well as for vaccine design.

“The more unique antibodies may be a lot harder to evade, which is important to consider as we think about the design of better therapies and vaccines,” said Elledge.

Reference: “Germline-encoded amino acid-binding motifs drive immunodominant public antibody responses” by Shrock EL et al., 6 April 2023, Science.
DOI: 10.1126/science.adc9498

Funding: This research was supported by the SARS-CoV-2 Viral Variants Program and the Value of Vaccine Research Network, the MassCPR, the National Institutes of Health (1P01AI165072, K99DE031016, AI139538, AI169619, AI170715, and AI170580), the National Science Foundation (Graduate Research Fellows Program), Pemberton-Trinity Fellowship, Sir Henry Wellcome Fellowship (201387/Z/16/Z), Jane Coffin Childs Postdoctoral Fellowship, Burroughs Wellcome Career Award in Medical Sciences. Elledge is an Investigator with the Howard Hughes Medical Institute.

Disclosures: Elledge and co-author Tomasz Kula are founders of TSCAN Therapeutics and ImmuneID. Elledge is a founder of MAZE Therapeutics and Mirimus, and serves on the scientific advisory board of Homology Medicines, TSCAN Therapeutics, MAZE Therapeutics, none of which impact this work. Shrock was a consultant for ImmuneID. Elledge and Kula are inventors on a patent application filed by the Brigham and Women’s Hospital (US20160320406A) that covers the use of the VirScan library to identify pathogen antibodies in blood.
 

Heliobas Disciple

TB Fanatic
(fair use applies)


New Side Effect of COVID-19 Discovered: “Face Blindness”
By Dartmouth College
April 6, 2023

A Dartmouth College study discovered impairments in both face recognition and navigational abilities.

A recent Dartmouth study published in the journal Cortex has revealed that COVID-19 can lead to difficulties in face recognition and navigation.

It is well established that COVID-19 can result in various neurological issues, such as the inability to detect odors and flavors, and cognitive impairments such as “brain fog,” which encompasses reductions in attention, memory, speech, and language abilities. However, the new study is the first to report instances of “prosopagnosia,” commonly referred to as face blindness, among individuals who have experienced symptoms consistent with COVID-19.

The researchers worked with Annie, a 28-year-old customer service representative and part-time portrait artist, who was diagnosed with COVID-19 in March 2020 and suffered a symptom relapse two months later. Shortly after the relapse, Annie noticed difficulty with face recognition and navigation.

“When I first met Annie, she told me that she was unable to recognize the faces of her family,” says lead author Marie-Luise Kieseler, a graduate student in the department of psychological and brain sciences and member of the Social Perception Lab at Dartmouth. Annie recounted the time when she was at a restaurant meeting her family for the first time after having COVID-19. She didn’t recognize them, and when she walked past them again, her father called out to her. “It was as if my dad’s voice came out of a stranger’s face,” says Annie, who now relies on voices to recognize people that she knows.

Annie also experienced navigational deficits after having COVID-19. She has had difficulty remembering where particular sections in her grocery store are and relies on Google Maps and its pin function to remember where she parks her car.

“The combination of prosopagnosia and navigational deficits that Annie had is something that caught our attention because the two deficits often go hand in hand after somebody either has had brain damage or developmental deficits,” says senior author Brad Duchaine, a professor of psychological and brain sciences and principal investigator of the Social Perception Lab at Dartmouth. “That co-occurrence is probably due to the two abilities depending on neighboring brain regions in the temporal lobe.”

The research team conducted a series of tests with Annie to evaluate her problems with face recognition and determine whether she also has difficulties with other perceptual or cognitive abilities.

Recognizing familiar and learning the identities of unfamiliar faces was especially challenging for Annie. For one of the tests, Annie was sequentially presented with 60 images of celebrity faces and was asked to name them. Afterward, she was presented with a list of the celebrities featured in the test to see if she knew them. Annie correctly identified 29% of the 48 celebrities whom she was familiar with as compared to most people, who can correctly identify 84% of familiar celebrities.

The second test was a doppelganger test. Annie was shown a celebrity’s name and then presented with images of two faces: the face of a celebrity and that of someone similar, and was then asked to identify which face was the famous person. She identified the celebrity in 69% of the 58 trials, as compared to 87% in the control group.

Annie’s more limited ability to learn and then recognize unfamiliar faces was demonstrated using the Cambridge Face Memory Test. In the test, participants learn six men’s faces and then they are asked to discriminate between the learned faces and other faces. On average, people are usually able to identify 80% correctly while Annie was only able to identify 56% correctly.

“Our results from the test with unfamiliar faces show that it wasn’t just that Annie couldn’t recall the name or biographical information of a famous person that she was familiar with, but she really has trouble learning new identities,” says Kieseler.

Her test scores in face detection, face identity perception, and object recognition were normal, indicating respectively, that Annie’s problems with faces are due to face memory deficits and are not a more generalized impairment.

Annie had flawless test scores in scene processing. When she was shown a set of landscapes and was then shown them again with a new set, she made no errors in identifying the landscapes she had been previously shown. “It’s likely, therefore, that her navigational impairments result from processes that might contribute to cognitive map representation rather than scene recognition deficits,” says Kieseler.

“This sort of dissociation like we’re seeing in Annie is seen in some people who have navigational deficits, where they can recognize where they are but when they’re asked where another place is relative to where they are right now, they struggle,” says Duchaine. “They have trouble understanding relationships between different places, which is a step beyond recognizing the place that you’re in.”

Annie also did really well in voice recognition tests in comparison to the controls, so the researchers think that her problems with face processing are most likely due to a deficit within the visual system.

“It’s been known that there are broad cognitive problems that can be caused by COVID-19, but here we’re seeing severe and highly selective problems in Annie,” says Duchaine, “and that suggests there might be a lot of other people who have quite severe and selective deficits following COVID.”

To determine if other people have experienced perception, recognition, and navigational problems due to long COVID, the research team obtained self-reported data from 54 individuals who had long COVID with symptoms for 12 weeks or more; and 32 persons who had reported that they had fully recovered from COVID-19.

Respondents were asked to rate themselves on statements about their visual perception and cognitive functioning, such as whether they could track characters on TV or navigate their environment, before and after they had contracted COVID-19. The research team measured the change in the before-and-after ratings and compared the results of the long COVID group to that of the fully recovered COVID group.

“Most respondents with long COVID reported that their cognitive and perceptual abilities had decreased since they had COVID, which was not surprising, but what was really fascinating was how many respondents reported deficits,” says Kieseler. “It was not just a small concentration of really impaired cases but a broad majority of people in the long COVID group reported noticeable difficulties doing things that they were able to do before contracting COVID-19 without any problems.”

“One of the challenges that many respondents reported was a difficulty with visualizing family and friends, which is something that we often hear from prosopagnosics,” says Duchaine, who is the co-founder of faceblind.org.

“Our study highlights the sorts of perceptual problems with face recognition and navigation that can be caused by COVID-19 — it’s something that people should be aware of, especially physicians and other health care professionals.”

Duchaine says, “As far as we know, nobody’s measured the sorts of high-level, visual processing abilities that are affected by COVID-19 that we focused on here in this paper, so if it’s happening in the visual system, it’s likely that selective deficits due to problems in other brain areas are occurring in some people as well.”

Reference: “Persistent prosopagnosia following COVID-19” by Marie-Luise Kieseler and Brad Duchaine, 9 March 2023, Cortex.
DOI: 10.1016/j.cortex.2023.01.012

Individuals experiencing perceptual or vision problems or navigational difficulties that they think may be caused by COVID-19 are welcome to contact the research team, who hope to do more research in this area. For more information about problems with face recognition such as prosopagnosia (face blindness) and other visual processing difficulties, visit: www.faceblind.org.
 

Heliobas Disciple

TB Fanatic
(fair use applies)


New Medical Codes for COVID-19 Vaccination Status Used to Track People, CDC Confirms
Zachary Stieber
April 6, 2023

Medical codes introduced during the COVID-19 pandemic to show when people are unvaccinated or undervaccinated for COVID-19 are being used to track people, the top U.S. public health agency has confirmed.

The U.S. Centers for Disease Control and Prevention (CDC) made the confirmation in emails that The Epoch Times obtained through a Freedom of Information Act request.

The CDC had said in documents and public statements that the goal of the new codes, in the International Classification of Diseases (ICD) system, was “to track people who are not immunized or only partially immunized.”

The CDC now says it does not have access to the data, but that health care systems do.

“The ICD codes were implemented in April 2022, however the CDC does not have any data on the codes and does not track this information,” CDC officials said in the emails.

“The codes were created to enable healthcare providers to track within their practices,” the officials added.

The emails were sent to news outlets. The CDC has not answered queries from The Epoch Times about the codes, which the CDC added to the U.S. ICD system in 2022.

The CDC proposed the codes in 2021. “There has been interest expressed in being able to track people who are not immunized or who are only partially immunized,” Dr. David Berglund, a CDC medical officer, said during a meeting about the proposal.

One code is for being “unvaccinated for COVID-19.” Another is for being partially vaccinated, or not having received a primary series of a COVID-19 vaccine.

In comments to the CDC about the proposal, health care providers said they supported adding the codes—with some detailing how they’d be used.

Identifying people who are unvaccinated or undervaccinated for COVID-19 “will help health insurance providers identify emollees [sic] who may benefit from outreach and further education about vaccination,” Danielle Lloyd, a senior vice president at America’s Health Insurance Plans (AHIP), and Adam Myers, senior vice president at the Blue Cross Blue Shield Association, said in a joint letter to the CDC.

“Creating ICD-10 codes that can be tracked via claims would provide health insurance providers key information to help increase immunization rates,” they added.

In another missive, Nancy Andersen, a director with Kaiser Permanente Health Plan and Hospitals, and Erica Eastham, executive director at The Permanente Federation LLC, told the CDC: “These codes provide valuable data for understanding immunization rates and for follow-up with under-immunized patients.”

Andersen and Eastham urged the CDC to advise providers entering one of the new codes to also enter an additional code indicating why a person was unvaccinated or undervaccinated, with reasons including due to a contraindication or due to “belief or group pressure.”

The comments were obtained by The Epoch Times through the Freedom of Information Act.

Most of the providers and other health care groups, including the American Health Information Management Association (AHIMA), that commented did not respond to inquiries.

AHIP declined to say what education it offered to people tracked through the new codes. A spokeswoman pointed to a Feb. 28, 2022, article that outlines steps providers have taken to promote vaccination.

The codes are part of the ICD’s 10th edition. The World Health Organization of the United Nations holds the copyright for ICD-10 but has allowed the U.S. government to adopt the edition, according to the CDC. The new codes are not part of the World Health Organization’s ICD.

All health care entities covered by the Health Insurance Portability and Accountability Act must use the U.S. version of the ICD. The U.S. version is updated at least once a year. Coded ICD data from providers enable public health officials to “conduct many disease-related activities,” according to the CDC. Purposes include enabling a doctor seeing a new patient to easily retrieve the patient’s medical history.

Support

Health care officials largely said they supported adding the codes because being unvaccinated or undervaccinated was a “risk factor.”

“AHIMA supported the new codes for underimmunization for COVID-19 status because being unvaccinated or partially vaccinated because this status is a health risk factor, increasing the individual’s risk of morbidity and mortality,” a spokeswoman for AHIMA told The Epoch Times via email.

“The ICD-10-CM coding system includes codes for many health risk factors, and being underimmunized for COVID-19 status represents another type of risk factor. It is important to be able to identify factors influencing a patient’s health status so that healthcare providers are aware of the person’s increased risk,” the spokeswoman added.

Some experts have said there is no medical indication for the new codes, given the small risk most Americans face from COVID-19.

“I have a hard time clinically seeing the medical indication of using them,” Dr. Todd Porter, a pediatrician, told The Epoch Times previously. “We do not do this for influenza, which in the younger age groups has a higher IFR [infection fatality ratio] than COVID-19. Using these codes also disregards the contribution of natural immunity which research evidence shows is more robust than vaccine immunity.”

CDC Refuses to Answer Members of Congress

The CDC, meanwhile, has refused to answer questions from members of Congress about the codes.

Rep. Chip Roy (R-Texas) and nine other members said they were concerned about the federal government apparently gathering data on the personal choices of Americans and said they believe the data “serves no sincere purpose in treating patients’ medical conditions.”

“The ICD system was originally intended to classify diagnoses and reasons for visiting the doctor, not to conduct surveillance on the personal medical decisions of American citizens. Given the profound uncertainty and distrust felt by many Americans toward the CDC and the medical apparatus at large, it is important for the CDC to make clear the intent and purpose of these new codes,” the members said, asking for answers to questions such as what steps the CDC is taking to make sure Americans’ private health information is protected.

The CDC has not replied to the Feb. 14 letter, members told The Epoch Times.

“I have asked five simple questions about the CDC’s unprecedented tracking of why Americans declined the COVID-19 vaccine. The CDC has so far refused to answer these basic questions. The American people deserve answers on what data CDC is gathering on Americans and why,” Roy told The Epoch Times in an emailed statement.

“The American people deserve to know what the CDC is doing with their personal data. It has now been more than a month and a half, and the CDC still refuses to tell us why it is tracking Americans’ reasons for not taking the COVID-19 vaccine,” added Rep. Josh Brecheen (R-Okla.). “The CDC must be held accountable to the American taxpayer.”
 

Heliobas Disciple

TB Fanatic
(fair use applies)


COVID caused brain damage in 2 infants infected during pregnancy -US study
Julie Steenhuysen
Thu, April 6, 2023, 1:20 PM EDT

CHICAGO (Reuters) - Researchers at the University of Miami reported on Thursday what they believe are the first two confirmed cases in which the SARS-CoV-2 virus crossed a mother's placenta and caused brain damage in the infants they were carrying.

Doctors previously had suspected this was possible, but until now, there was no direct evidence of COVID-19 in a mother's placenta or an infant's brain, the team told reporters at a news briefing.

The babies were born to young mothers who tested positive for the virus during their second trimester at the height of the pandemic's Delta wave in 2020, before vaccines were available. The case studies were published in the journal Pediatrics.

Several viruses are known to be capable of crossing the placenta and causing fetal brain damage, including Cytomegalovirus, Rubella, HIV and Zika. The SARS-CoV-2 virus has been detected in adult brain tissue, and some experts had suspected it could also damage fetal brain tissue.

"This is the first time that we've been able to demonstrate the virus in a fetal organ with transplacental passage," Dr. Michael Paidas, chair of obstetrics and gynecology at the University of Miami, told the briefing. "That's why we think this is so important."

The newborns had seizures from the first day of life. However, unlike Zika, the babies were not born with microcephaly, a condition marked by small head size. Instead, microcephaly developed over time as their brains stopped growing at a normal rate, the team said.

Both infants had severe developmental delays. One of the children died at 13 months, and the other was in hospice care, the team said.

Neither of the infants tested positive for the SARS-CoV-2 virus, but they did have high levels of COVID antibodies in their blood, Dr. Merline Benny, a neonatologist and assistant professor of pediatrics at the University of Miami, told the briefing. She said that suggests the virus crossed from the mother, through the placenta and to the baby.

The team found evidence of the virus in both mothers' placentas. An autopsy of the child's brain who died revealed COVID virus in the brain, suggesting direct infection caused the injuries, Benny said.

As for the mothers, although both tested positive for the virus, one woman had only mild symptoms and carried the baby full term while the other was so sick that doctors had to deliver the baby at 32 weeks of gestation.

Dr. Shahnaz Duara, an obstetrician and gynecologist at the University of Miami, said she believed the cases were rare, but urged women who had been infected during their pregnancies to inform their children's pediatricians to check for developmental delays.

"We know that things can be fairly subtle up to seven or eight years of age, until kids go to school," she said.

The team also urged women who were considering pregnancy to get vaccinated against COVID, and said pregnant women should consider vaccination.

It was not yet clear whether the injuries caused during pregnancy were unique to the Delta variant of SARS-CoV-2 or could occur with Omicron-related variants.
 

Heliobas Disciple

TB Fanatic
(fair use applies)


What to know about the XBB.1.16 COVID variant causing concern in India
INGRID HEIN | MEDPAGE TODAY - ABC News
Thu, April 6, 2023, 11:45 AM ED

The World Health Organization is monitoring XBB.1.16, an omicron subvariant that has been detected in over 20 countries and is contributing to a recent surge of COVID-19 cases in India.

Known as "Arcturus," XBB.1.16 has been listed as a WHO variant under monitoring since March 22, with 800 sequences of the omicron subvariant currently analyzed across 22 countries.

"Most of the sequences are from India and XBB.1.16 has replaced the other variants that are in circulation, so this is one to watch," said Dr. Maria Van Kerkhove, technical lead for COVID-19 response at the WHO, during a virtual press briefing last week.

XBB.1.16 has high infectivity and pathogenicity, Van Kerkhove noted.

In the U.S., XBB.1.16 has been reported in several states, including California, Washington, New Jersey, New York, Virginia and Texas, according to a tracker run by Dr. Rajendram Rajnarayanan of the New York Institute of Technology. On Twitter, he estimated that the lineage comprises 2.9% of current U.S. cases.

Still, despite contributing to a spike in cases in Southeast Asia in recent weeks, the WHO reported that the death count in the region has gone down by 6% in the last four weeks.

"So far reports do not indicate a rise in hospitalizations, ICU admissions, or deaths due to XBB.1.16," the WHO report stated. "Further, there are currently no reported laboratory studies on markers of disease severity for XBB.1.16."

However, according to Van Kerkhove, "we have to remain vigilant."

While she pointed out that there hasn't been a change in severity, "we have to have systems that are in place that have strong surveillance, so that we can track variants -- the known variants that are in circulation, and to detect new ones so that we can have agile systems to scale up or scale down the need for clinical care, making sure that we have good antivirals that are in use and given to patients who need them when they need them to prevent severe disease."

XBB.1.16 is a recombinant variant from BA.2.10.1 and BA.2.75. It has three additional mutations in the SARS-CoV-2 spike protein (E180V, F486P and K478R) compared with its parent lineage, XBB. It is very similar in profile to XBB.1.5, which currently comprises 85% of U.S. cases and 45% of global cases.

While XBB.1.16 and XBB.1.5 both share a common parent and common mutation in F486P, it is the K478R mutation in XBB.1.16 that appears to be responsible for the spike in cases in India, the WHO said.

"Mutations at position 478 of the SARS-CoV-2 spike protein have been associated with decreased antibody neutralization, increased transmissibility, and pathogenicity," the WHO explained in the update.

According to the Memorial Sloan Kettering Library, "Recombinant viral variants can occur when a single person is infected with multiple distinct variants at the same time, allowing the two different variants to interact during replication. When their genetic materials mix they create a new hybrid, or a recombinant variant. There's nothing inherently 'worse' about recombinant variants -- they could be more or less fit than their parents, or have the same fitness."

Although XBB.1.16 is currently making headlines worldwide, other variants, including XBB.1.9.1, are also currently on both the WHO's and the Centers for Disease Control and Prevention's radar.
 

Heliobas Disciple

TB Fanatic
(fair use applies)


India Reports More Than 5,335 New COVID-19 Infections In the Last Few Hours With Hospitalizations Now Increasing And Doctors Are Getting Infected Too
Thailand Medical News
April 6, 2023

According to official reports from Indian health authorities, there were more than 5,335 new COVID-19 infections in the last 24 hours. Considering that India has a population of more than 1.4 billion people and that in most crowded cities there is very little precautions being undertaken coupled with the fact there is very little testing and India’s notoriety for lying and concealing COVID-19 statistics is so well established…. we can easily conclude that the actual figures must be much higher.






A latest survey that was reported to the media shows that COVID cases in India may be underreported by 300 Percent!



The SARS-CoV-2 XBB.1.16 sub-lineage is the predominant variant in India at the moment accounting for about 52.3 percent of all sequencings.

View: https://twitter.com/RajlabN/status/1643653452080218114



But it is not the XBB1.16 sub-lineage that people should be worried about thought it can cause sufficient havoc as a result of being more transmissible and slightly more pathogenic than the other XBB sub-lineages as a result of mutations in its ORF 9 proteins. Those in the vulnerable groups would have very little chances of evading its effects.

What is more concerning however is that the XBB.1.16 itself is evolving rather rapidly and spawning so many newer sub-lineages with different mutations.


We at Thailand Medical News strongly believe that it is evolving to completely evade T Cell immunity and also to destroy T Cells.


We strongly believe that the next spawns from the XBB.1.16 sub-line with the right viral fitness and mutations will most probably be what we can truly call as SARS-CoV-3 as they will resemble airborne HIV that is more virulent than even HIV itself.

In meanwhile, we also have more good news. As hospitals start to see a gradual rise in COVID hospitalizations, COVID-19 News reports are emerging that doctors and healthcare staff are getting infected as well and some are getting sick. (Can’t wait for that situation to duplicate itself in Thailand after the Songkran break as love to see a certain female endocrinologist and her hypocritical rude sister also get seriously infected!).

It was reported that in Kerala, India while hospitals are seeing rising caseloads, doctors too are getting infected.


We will actually see the real COVID-19 situation in a couple of weeks’ time in India and also globally as the spawns of the XBB.1.16 are also emerging in other countries and its just a matter of weeks.

[...]
 

Heliobas Disciple

TB Fanatic
(fair use applies)


New Research Uncovers Potential Explanation for COVID Vaccine Blood Clot Connection
By Flinders University
April 7, 2023

Scientists identify key differences in immune responses to the AstraZeneca and Pfizer vaccines.


A recent study conducted by a team from SAHMRI and Flinders University in Australia has revealed significant variations in the way the AstraZeneca and Pfizer COVID-19 vaccines affect the immune system. The findings, published in Cell Reports Medicine, are part of the COVID-19 Vaccine Immune Responses Study (COVIRS) and were based on the analysis of the immune responses of 102 adults of various ages residing in South Australia, where there was no SARS-CoV-2 community transmission at the time of the study.

The participants in the study had their blood samples collected immediately after receiving each dose of either the Oxford/AstraZeneca or Pfizer/BioNTech COVID-19 vaccine, in order to evaluate their early immune response. Further tests were conducted 28 days after each immunization to measure the activity of B and T cells, both of which play a crucial role in the immune response. B cells produce antibodies, while T cells target and eliminate infected cells.

The vaccines are alike in the sense that they induce the immune system to recognize and protect against the SARS-CoV-2 virus, but they differ in how this is achieved. The Pfizer vaccine uses mRNA technology to induce host cells to produce the SARS-CoV-2 Spike protein, while the AstraZeneca vaccine uses a harmless virus (a chimpanzee adenovirus) to encode the Spike protein.

Head of SAHMRI’s Systems Immunology Laboratory and Flinders University Professor David Lynn led the study, using a method of biological analysis known as ‘multi-omics’ to examine immune responses in many different ways in thousands of blood samples. Professor Lynn says this comprehensive analysis of immune responses to these different vaccines has revealed lots of new information that’ll help inform future vaccine design.

“After the first dose, we were surprised to find the Oxford/AstraZeneca vaccine elicits an unexpected memory-like response in the immune system, recognizing the vaccine as if it’s something it’s seen before,” says Professor Lynn, from the College of Medicine and Public Health at Flinders University.

“This response is targeted against the adenovirus vector in the vaccine, not the Spike protein and the intensity of this response correlates with the expression of proteins that act as a pre-cursor to thrombosis, or blood clotting. While Vaccine-induced immune thrombotic thrombocytopenia (VITT) is an extremely rare side effect associated with the Oxford/AstraZeneca vaccine that none of the participants developed during the study, this research offers a potential explanation for the connection between the Oxford/AstraZeneca vaccine and the cases of VITT that have been reported.”

The study also found those who’d only had two doses of the Oxford/AstraZeneca vaccine generally produced lower amounts of antibodies and less of a specialized type of T-cell that helps with antibody production; compared to those who had two doses of the Pfizer/BioNTech vaccine.

However, this was rectified once they had their third booster dose of an mRNA vaccine, illustrating the importance of booster doses. The study added evidence to the notion that COVID-19 vaccines offer some people more effective protection than others.

The reasons for this variability are not well understood, but Professor Lynn says age is a factor, with older people generally having a lower immune response after two doses. Fortunately, a third booster dose was highly effective at overcoming this. Immune responses induced immediately after vaccination predicted the subsequent B and T cell response to the vaccine measured a month later.

“One to two days after initial vaccination we measured gene expression responses in the blood which correlated with adaptive immune responses that mediate protection 28 days later,” Professor Lynn says.

A further surprise to researchers was the finding that feeling unwell after a vaccine dose may in fact be linked to its effectiveness.

“People who showed symptoms of fatigue and fever immediately after the third dose were more likely to have better T-cell responses. T-cells play a vital role in vaccine efficacy as they can directly kill viral cells,” Professor Lynn said.

Overall, this project has provided important new insights into the early immune responses to these vaccines and offers a greater understanding of how they work to protect against COVID-19.

Reference: “A systems immunology study comparing innate and adaptive immune responses in adults to COVID-19 mRNA and adenovirus vectored vaccines” by Feargal J. Ryan, Todd S. Norton, Conor McCafferty, Stephen J. Blake, Natalie E. Stevens, Jane James, Georgina L. Eden, Yee C. Tee, Saoirse C. Benson, Makutiro G. Masavuli, Arthur E.L. Yeow, Arunasingam Abayasingam, David Agapiou, Hannah Stevens, Jana Zecha, Nicole L. Messina, Nigel Curtis, Vera Ignjatovic, Paul Monagle, Huyen Tran, James D. McFadyen, Rowena A. Bull, Branka Grubor-Bauk, Miriam A. Lynn, Rochelle Botten, Simone E. Barry and David J. Lynn, 16 February 2023, Cell Reports Medicine.
DOI: 10.1016/j.xcrm.2023.100971

The study was a major collaboration involving SAHMRI, Flinders University, Murdoch Children’s Research Institute, The University of Melbourne, The University of Adelaide, Basil Hetzel Institute for Translational Health Research, University of New South Wales, The Kirby Institute, Alfred Hospital, Monash University, AstraZeneca and the Royal Adelaide Hospital.

The team wishes to express its gratitude to all participants and funders, including Bioplatforms Australia, AstraZeneca, The Hospital Research Foundation and the Flinders Foundation.
 

Heliobas Disciple

TB Fanatic
(fair use applies)


Another COVID-19 booster shot may be coming. But interest is waning
Rong-Gong Lin II, Luke Money, Sean Greene - Los Angeles Times
Fri, April 7, 2023, 8:00 AM EDT

As government officials close the book on the emergency phase of the COVID-19 pandemic, health authorities are turning their attention to the next chapter of the vaccination campaign.

Though nothing is etched in stone, federal officials are considering the authorization of another booster shot this spring.

The timing of that decision — and who would be eligible — remains unclear. But for older residents or those with underlying health conditions that make them more likely to develop a severe COVID-19 illness, another booster could provide peace of mind and an additional jolt of protection.

"Lots of people at higher risk are asking whether or not they need another dose. And we're waiting for guidance on that," Los Angeles County Public Health Director Barbara Ferrer said.

Authorities in Britain have already green-lighted a spring booster shot — but only for nursing home residents, seniors 75 or older or those who are immunosuppressed and at least 5 years old.

"This year’s spring program will bridge the gap to the planned booster program in the autumn, enabling those who are most vulnerable to be well-protected throughout the summer," Dr. Wei Shen Lim, chair of Britain's Joint Committee on Vaccination and Immunization, said in a statement.

Canada's National Advisory Committee on Immunization is suggesting a similar approach: making a spring booster available for those 65 or older as well as immunosuppressed adults and nursing home residents.

It remains to be seen how much of an appetite there could be for an additional booster in the U.S. In California, 45% of vaccinated seniors have received the updated booster shot. Among all age groups, only 25% of eligible Californians — that is, people who have completed their primary vaccination series — have rolled up their sleeves since the updated bivalent doses became available in September.

Even though uptake of the updated booster shot in Canada has also been relatively low, officials there said it would be beneficial to offer additional doses.

"We have historically seen patterns of waning protection against severe disease by six months after the last dose, particularly in older adults without prior infection," Dr. Shelley Deeks, chair of Canada's National Advisory Committee on Immunization, said in a statement.

Emerging data demonstrate that those who get the bivalent booster shot are better protected against hospitalization and death, with the benefit particularly pronounced among older individuals.

Among people age 65 to 79 in L.A. County, for instance, those who got the updated booster had one-tenth the risk of being hospitalized compared with those who are unvaccinated, and roughly half the risk of being hospitalized compared with those who are vaccinated but haven't received the bivalent booster.

Even among younger adults, in their 30s and 40s, the benefits were noticeable. Those who got the updated booster had one-sixth the chance of being hospitalized than unvaccinated people, and roughly half the chance of being hospitalized compared with vaccinated people who hadn't gotten the updated booster.

The same goes with deaths. Those age 65 to 79 who got the updated booster were about one-tenth as likely to die from COVID-19 compared with unvaccinated people. They were roughly half as likely to die compared with vaccinated people who hadn't received the updated booster.

Even with the termination of many COVID-19 emergency declarations, including in California, officials are stressing vigilance. And vaccinating those most at risk remains a key focus moving forward — particularly as the disease continues to kill thousands of people a week worldwide.

"These [deaths] are largely among individuals who are of older age, they may not have been vaccinated or received the full number of doses that are required for them at their age," said Maria Van Kerkhove, the World Health Organization’s technical lead on COVID-19. "So the threat remains."

If authorized by U.S. health officials, additional doses of bivalent vaccine — designed to protect against Omicron subvariants that once dominated the coronavirus landscape — will, like in Britain and Canada, probably be made available for older people or others at higher risk of severe COVID-19 complications.

Dr. Peter Hotez, a pediatrics, molecular virology and microbiology professor at Baylor College of Medicine, has been a prominent supporter of making a second updated booster shot available, given what's known about COVID vaccines' waning protection over time.

"Uptake of the second [updated booster] may only be around 10%," Hotez tweeted. "But for those who want it — especially the immunocompromised — they should have that option."

Health officials have for months touted the benefits of the bivalent boosters, saying they provide added protection against infection, and especially against severe illness.

Still, there appears to be booster fatigue, even in highly vaccinated areas. A Times data analysis showed only two of California's 58 counties had seen even 40% of their eligible residents get an updated booster as of March 31.

By comparison, about 73% of Californians completed their primary vaccination series, and 61% of vaccinated residents have gotten at least one booster shot, according to data from the state Department of Public Health.

Some residents, especially those boosted recently, may have been unclear that the latest shot was formulated differently, or felt they didn't need it.

Hotez said he's struck by how many people don't know an updated booster came out in September.

"We still have a lot of vaccine education that needs to be done," he wrote.

Others could simply be sick of rolling up their sleeves after already receiving multiple shots over the last two years.

COVID-19 conditions may also have played a role. Though California did see a coronavirus surge in the late autumn, it was short-lived and came nowhere near the devastation seen earlier in the pandemic.

The reduced severity of COVID-19 this last winter is likely due to a combination of factors, including the fact that older vaccine shots and earlier infections still provide a considerable degree of immunity; a plentiful supply of anti-COVID therapeutic drugs such as Paxlovid; and the relative stability of the dominant coronavirus strain — which has remained some subvariant of Omicron for more than a year.

As has been the case throughout the vaccine rollout, booster administration differs across California. The Times' data analysis shows uptake has been higher in the San Francisco Bay Area and lower in the Inland Empire and San Joaquin Valley. Coastal Southern California counties are roughly in line with the statewide rate.

Even in the Bay Area, which has consistently boasted robust levels of vaccine uptake, only about 35% of eligible residents have gotten the latest shot.

About 33% of eligible residents in Santa Clara County received the updated booster, as did 36% of those in Alameda County and just under 40% in San Mateo County.

The state's booster leaders were Marin and San Francisco counties, both at about 42%.

Southern California's coastal counties — including Los Angeles, San Diego, Orange and Ventura — all have about the same rate of uptake: 24%. Santa Barbara County's is slightly higher, at 25%.

The Greater Sacramento area had a booster uptake rate of 27%, roughly in line with the overall statewide figure.

The San Joaquin Valley, however, lags well behind. The updated booster rate there was around 16%, the worst of the five regions defined by the state Department of Public Health.

The same was true in the Inland Empire. Riverside and San Bernardino counties have seen far lower updated booster coverage than their coastal neighbors, at 19% and 17%, respectively.

Although booster rates are not what officials had hoped for, authorities say it's significant that large majorities of a number of highly populated areas did complete the primary vaccination series.

There was a time when getting so many people vaccinated seemed a daunting prospect. L.A. County, for instance, initially set a target of administering at least one shot to 80% of all residents age 16 or older.

That goal long seemed elusive, but the latest county data show that 85% of all county residents 5 or older have received at least one shot, and 77% have completed their primary vaccination series.

And within this group, 46% have received at least one additional dose, whether it be the older or the updated bivalent booster.

For the public, there's an expectation that COVID-19 vaccines may mirror flu shots in the U.S.: one dose, formulated and administered annually.

That approach could bear some fruit. A recent survey from the Kaiser Family Foundation found 53% of adults said they were somewhat or very likely get a COVID vaccine if it were offered annually.

That would be similar to the typical uptake of the flu vaccine. About 48% of U.S. adults have received the flu shot this season, according to the U.S. Centers for Disease Control and Prevention.

"We can, as we all know, get both vaccines on the same day, one in each arm," Ferrer said. "And then we'll have some protections going into what is usually the season with the highest number of respiratory viruses."
 

Heliobas Disciple

TB Fanatic
(fair use applies)


India asks states to ramp up testing as COVID-19 cases climb
Reporting by Shilpa Jamkhandikar and Sudipto Ganguly
Fri, April 7, 2023, 7:26 AM EDT

MUMBAI (Reuters) - India's federal government asked states to identify emergency hotspots and ramp up-testing for COVID-19, after the country recorded its highest daily case count since September, a Reuters tally showed on Friday.

There were 6,050 new cases of COVID-19 in the last 24 hours, the federal health ministry said on Friday, continuing a sharp upward trend since a lull last year.

At a meeting to review the degree to which the states are prepared, health minister Mansukh Mandaviya asked them to ramp up genome testing and conduct mock drills in hospitals, a government statement said.

Daily new cases have nearly tripled from around 2,000 at the end of March.

The prevalence of XBB.1.16, classified as a variant of interest by the World Health Organisation, increased from 21.6% in February to 35.8% in March, the health ministry said, adding there that was no evidence of an increase in hospitalisations or deaths.

Active cases totalled more than 28,300 with 14 deaths during the last 24 hours, taking the country's official death toll from the disease to 530,943.

India has recorded more than 44.7 million confirmed cases of COVID-19 since the start of the pandemic three years ago, the third-highest tally after the United States and China.
 

Heliobas Disciple

TB Fanatic
(fair use applies)


Chinese Load Cow's Milk with mRNA Exosomes--Successfully Immunize Mice
COVID-19 mRNA Vaccine Assault Possible Through Food Supply

Peter A. McCullough, MD, MPH™
21 hr ago

The nation’s food supply can be manipulated by public health agencies to influence population outcomes. A great is example is fortification of cereal grains with folic acid — the synthetic form of folate — which successfully reduced the incidence of neural tube defects (e.g. spina bifida). Now an oral route of administration is being considered specifically for COVID-19 vaccination using mRNA in cow’s milk.

Zhang and colleagues have demonstrated that a shortened mRNA code of 675 base pairs could be loaded into phospholipid packets called exosomes derived from milk and then using that same milk, be fed to mice. The mice gastrointestinal tract absorbed the exosomes and the mRNA must have made it into the blood stream and lymphatic tissue because antibodies were produced in fed mice against SARS-CoV-2 Spike protein (receptor binding domain).



An oral vaccine for SARS-CoV-2 RBD mRNA-bovine milk-derived exosomes induces a neutralizing antibody response in vivo. Quan Zhang, Miao Wang, Chunle Han, Zhijun Wen, Xiaozhu Meng, Dongli Qi, Na Wang, Huanqing Du, Jianhong Wang, Lu Lu, Xiaohu Ge bioRxiv 2022.12.19.517879; doi: An oral vaccine for SARS-CoV-2 RBD mRNA-bovine milk-derived exosomes induces a neutralizing antibody response in vivo

From a scientific perspective, these experimental steps taken by the Chinese were a stunning success. However, given the damage mRNA vaccines have generated in terms of injuries, disabilities, and deaths, these data raise considerable ethical issues. The COVID States project has shown that 25% of Americans were successful in remaining unvaccinated. This group would have strong objections to mRNA in the food supply, particularly if it was done surreptitiously or with minimal labelling/warnings. Children could be targeted with easily administered oral vaccine dosing or potentially get mRNA through milk at school lunches and other unsupervised meals.

For those who have taken one of the COVID-19 vaccines, having milk vaccines as an EUA offering would allow even more loading of the body with synthetic mRNA which has been proven resistant to ribonucleases and may reside permanently in the human body.

These observations lead me to conclude that mRNA technology has just entered a whole new, much darker phase of development. Expect more research on and resistance to mRNA in our food supply. The Chinese have just taken the first of what will probably be many more dangerous steps for the world.

An oral vaccine for SARS-CoV-2 RBD mRNA-bovine milk-derived exosomes induces a neutralizing antibody response in vivo Quan Zhang, Miao Wang, Chunle Han, Zhijun Wen, Xiaozhu Meng, Dongli Qi, Na Wang, Huanqing Du, Jianhong Wang, Lu Lu, Xiaohu Ge bioRxiv 2022.12.19.517879; doi: https://doi.org/10.1101/2022.12.19.517879

COVID States Project Gives New Hope to Unvaccinated Study Shows 25% Declined Shots--A Healthy Minority
 
Top